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1. Introduction 
Pyridine derivatives have attracted considerable interest 
because of their great practical usefulness due to their various 
biological activities. Among them, fused analogues are often 
much more biologically active. More particularly, 
thienopyridines have been shown to exhibit a large variety of 
biological activities.1 Nowadays the chemistry of the [2,3-b]-
isomers is better known in comparison with  the [3,2-b]-isomers. 
The diversity of biological activities gave an impulse to the 
development of convenient synthetic routes for the synthesis of 
the thieno[3,2-b]pyridine system. Most of the methods for the 
synthesis of thieno[3,2-b]pyridines are based on the use of 
readily accessible 3-aminothiophenes or their N-derivatives2 and 
only few synthesis have already been described starting from the 
pyridine ring.3 For example, Fort et al. have reported a three-step 
process allowing the construction of the thiophene ring. The key 
step was the almost regioselective  lithiation–bromination of the 
3-methylthiopyridine induced by the BuLi-LiDMAE superbase 
(DMAE: 2-(dimethylamino)ethanol)  followed by a Sonogashira 
coupling and a halogenocyclization to give the corresponding 2- 
substituted (Ph or TMS) 3-halothieno[3,2-b]pyridines.3d 
 
In the last few years our group has been interested in the 
synthesis of thieno[3,2-b]pyridine derivatives. We have reported 
a one-pot two-step synthesis of the methyl 3-amino-6-
bromothieno[3,2-b]pyridine-2-carboxylate from 5-bromo-3-
nitropicolinonitrile and methyl thioglycolate in DMF/KOH(aq).4 
This product  was obtained in excellent yield and it was further 
functionalized by C-C (Suzuki, Sonogashira)5a,b or C-N 
(Buchwald-Hartwig)5c couplings, to give new derivatives 
exhibiting inhibitory growth activity in human tumor cell lines.5 
Herein, we describe a new and general method for the 
synthesis of thieno[2,3-b] and [3,2-b]pyridines bearing a 
(hetero)aryl substituent in the 2-position, from 2- or 3-
chloro(hetero)arylethynylpyridines obtained by Sonogashira 
coupling of 2,3-dihalopyridines with (hetero)arylalkynes,  
followed by treatment with sodium sulfide (Na2S) as depicted in 
Scheme 1.  
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A simple and efficient three-step methodology is described for the first time for the synthesis of 
2-(hetero)arylthieno[2,3-b]  or [3,2-b]pyridines.  The first step is a Sonogashira coupling from 3-
bromo-2-chloropyridine or 2-bromo-3-chloropyridine with several (hetero)arylalkynes to obtain 
the corresponding 2- or 3-chloro(hetero)arylethynylpyridines. These were cyclized by treatment 
with Na2S affording the expected 2-(hetero)arylthienopyridines. As an improvement, these 
reactions were also performed in one-pot, without the isolation of the Sonogashira product, 
giving the thienopyridines in similar or better yields, reducing significantly the reaction time 
after the addition of Na2S. Further functionalizations were achieved in the thienopyridine system
either by bromination in the thiophene ring or chlorination in the pyridine ring via a N-oxide 
intermediate, allowing metal-catalyzed coupling reactions and/or nucleophilic substitutions. The 
functionalization of some substituents is also possible and as an example a 1,3-diarylurea was 
obtained from the reaction of an aniline derivative with an arylisocyanate. 
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Scheme 1. Strategy for the synthesis of 2-(hetero)arylthieno[2,3-b] 
and [3,2-b]pyridines. 
 
2. Results and discussion 
Optimization experiments were first carried out on the 
Sonogashira reaction6 of the 3-bromo-2-chloropyridine with 
phenylacetylene using PdCl2(PPh3)2 as the catalyst, CuI as the co-
catalyst. The best conditions were the ones presented in Scheme 
2, using Et3N as the base and the solvent, with only a slight 
excess of phenylacetylene (1.1 equiv.), as it is well known that an 
important side reaction, namely the Glaser-type oxidative 
dimerization of the alkyne, usually occurs in the presence of 
Cu(I).7 
Ph
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Scheme 2. Sonogashira coupling of 3-bromo-2-chloropyridine with 
phenylacetylene. 
 
The isolation of the 2,3-bis(phenylethynyl)pyridine as a minor 
product has been observed and its formation increases with the 
reaction time. 
Using these conditions various 2-chloro-3-ethynylpyridines 
were synthesized in moderate to good yields (Table 1, products 
1-13). The reaction time being quite low, the moderate yields that 
were obtained with some aryl and heteroarylalkynes were mostly 
related to the dimerization of the alkyne, and not to the formation 
of the di(hetero)arylethynylpyridine, as it occurred when 
phenylacetylene was used (Scheme 2). 
The synthesis of the corresponding 3-chloro-2-
ethynylpyridines was also performed, using the same conditions 
(Table 1, products 14-26). As expected, the yields were much 
higher when 2-bromo-3-chloropyridine was used as the starting 
material, due to the better activation of the bromine in the 2-
position for the Sonogashira coupling. Thus, all the expected 3-
chloro-2-(hetero)arylethynylpyridines were synthesized in very 
good to excellent yields from either electron-rich or electron-poor 
(hetero)arylalkynes (from 70% to 93%).  
The synthesis of annulated thiophene rings from ortho-
haloalkynyl antraquinones, benzenes, naphthalenes, and 
pyrazoles to give antrathiophenediones,8a benzo[b]thiophenes,8b,c 
naphthodithiophenes,8d,e and thieno[2,3-c]pyrazoles,8f 
respectively, has already been described using Na2S.  
In the present work the reaction of the Sonogashira coupling 
products 1-26 with Na2S overnight, gave the thieno[2,3-
b]pyridines 27-39 and the thieno[3,2-b]pyridines 40-52 in good 
to excellent yields (Table 1). This methodology was applied by 
us for the first time to the synthesis of thienopyridine derivatives. 
A plausible mechanism is a nucleophilic attack (SNAr) of the 
hydrosulfide ion on the ortho-chloroalkynylpyridine followed by 
an intramolecular addition on the triple bond but on the other 
hand an addition of the hydrosulfide ion to the triple bond may 
occur, followed by a SNAr/cyclization (Scheme 3).  
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Scheme 3. Plausible mechanisms for the synthesis of 2-
(hetero)arylthieno[2,3-b] or [3,2-b]pyridines from the ortho-
choroalkynylpyridines 
 
Unexpected results were obtained for the cyclization of the 
ortho-methoxylated Sonogashira coupling products 7 and 20: 
instead of the expected 2-(2-methoxyphenyl)thienopyridines, the 
cyclization with Na2S gave the corresponding hydroxylated 
thienopyridines 33 and 46 in good to high yields (Table 1), 
maybe due to the spatial proximity of the sulfide anion 
intermediate with the methoxy group. 
We have also used  this methodology  through  a one-pot 
procedure. Thus, after coupling the 2,3-dihalopyridines with 
(hetero)arylalkynes at 100 oC for 2h, Na2S was added to the 
reaction mixture without the isolation of the Sonogashira 
coupling product and the solution was allowed to stir at 130 ºC 
for a further 2h. Some examples were performed using these 
conditions and the thienopyridines 27, 28, 30-32, 36-41, 43-45 
and 49-52 were obtained in good to excellent yields (Table 2). 
The expected thienopyridines were purified by recrystallization 
or dry flash chromatography. The yields obtained under this one-
pot procedure were at least as good and often higher than those 
obtained when the reactions were performed with isolation of the 
Sonogashira coupling product. 
After adding Na2S, the reaction was much faster when 
performed in one-pot, as only 2h of heating were required for the 
reaction to reach completion. This is agreement with Müller et 
al.9 that for the synthesis of several annulated 4H-thiopyran-4-
ones by one-pot microwave-assisted reaction, from ortho-chloro 
or fluoro(hetero)aroylchlorides, alkynes and Na2S, postulated that 
the cyclizing step is assisted by Pd and/or Cu.  
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Table 1. Synthesis of 2-(hetero)arylthienopyridines 
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Table 2. Synthesis of 2-(hetero)arylthienopyridines in one-pot 
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Thieno[2,3-b]pyridines 
Yields 
Thieno[3,2-b]pyridines 
Yields 
One-
pot 
fashion 
Two-pot 
fashiona 
One-
pot 
fashion 
Two-pot 
fashiona 
27 85% 72% 40 94% 71% 
28 40% 36% 41 65% 60% 
30 45% 41% 43 80% 84% 
31 74% 59% 44 86% 87% 
32 62% 67% 45 84% 87% 
36 60% 57% 49 73% 56% 
37 70% 42% 50 77% 61% 
38 66% 68% 51 78% 66% 
39 66% 39% 52 69% 43% 
                                                                             a
 global yields calculated for the synthesis in two-pot of thienopyridines  
 
To valorize this work, some of the thienopyridines obtained 
were further functionalized. Our group is interested in the 
synthesis of di(hetero)arylureas from thienopyridine 
derivatives bearing an amine moiety. Indeed, it has been well 
established that urea derivatives have got a significant place in 
modern medicinal chemistry as they have been reported in the 
literature as anticancer agents,10 anticonvulsant11 and CXCR3 
antagonist.12 1,3-Diarylurea derivatives, and particularly in the 
thienopyridine series, were also reported as cell growth factor 
receptor tyrosine kinase inhibitors, as anticancer and/or 
antiangiogenic compounds.1f,13 The reaction of 2-(thieno[3,2-
b]pyridin-2-yl)aniline 43 with 4-methoxyphenylisocyanate was 
performed at room temperature and successfully provided the 
expected 1-(4-methoxyphenyl)-3-[2-(thieno[3,2-b]pyridin-2-
yl)phenyl]urea 53 in excellent yield (Scheme 4).  
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Scheme 4. Synthesis of the new 1,3-diarylurea 53 from thieno[3,2-
b]pyridine 43 and 4-methoxyphenylisocyanate. 
 
The halogenation of some thienopyridines was also 
performed. The presence of a bromine or a chlorine atom will 
allow further functionalizations by metal-catalyzed coupling 
reactions (C-C, C-N and C-O) or nucleophilic substitution, 
leading to the synthesis of new thienopyridine derivatives.  
The bromination in the 3-position of the 2-
phenylthienopyridines 27 and 40 was done using Br2 in dry 
ether at 0 ºC, affording the corresponding 3-bromo-2- 
phenylthienopyridines 54 and 55 in moderate yields (Scheme 
5). With 2-(pyridin-3-yl)thieno[2,3-b]pyridine 37, the expected 
3-bromo derivative 56 was obtained in a good yield (65%) 
using dry CH2Cl2 as the solvent due to the low solubility of the 
starting material. 
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Scheme 5. i: Br2 (1.1 equiv.), dry Et2O, 0ºC, 30-60 min. ii: dry 
CH2Cl2 used as the solvent. 
 
Compound 55 was already obtained by Fort et al.3d in a total 
yield of 32% in a three-step methodology starting from 3-
methylthiopyridine (that has to be previously synthesized by 
reacting 3-bromopyridine with tBuLi and dimethylsulfur). 
However this methodology implies the use of delicate reaction 
conditions (the use of nBuLi and tBuLi requires to work in 
extremely dry conditions, under argon, and at temperatures as 
low as -90ºC), and the reactions were not completely 
regioselective. In our case, product 55 was synthesized from 
the commercially available 2-bromo-3-chloropyridine also in 
three steps in a better total yield (40% through the one-pot 
procedure for compound 40), using simple and regioselective 
reactions. 
Chlorination in the 4-position of the thieno[2,3-b]pyridine 
32 was also performed, following a procedure via the 
preparation of the N-oxide using 3-chloroperoxybenzoic acid 
(MCPBA).14 After evaporation of the solvents the solid 
obtained was treated with POCl3 using CHCl3 as the solvent15 
to afford the 4-chlorothieno[2,3-b]pyridine 57 in high yield 
(Scheme 6). This will allow the functionalization of the 
pyridine ring of the system which is also important for the 
synthesis of biologically active compounds. 
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Scheme 6. Chlorination in the 4-position of thieno[2,3-b]pyridine 
32.  
 
 
3. Conclusion 
We have developed a general and efficient methodology for 
the synthesis of 2-(hetero)arylthieno[2,3-b] or [3,2-b]pyridines 
from 2,3-dihalopyridines, (hetero)arylalkynes and Na2S, that 
works also in a one-pot procedure, reducing significantly the 
time of the last steps. The compounds obtained were submitted 
to further functionalizations. A 1,3-diarylurea was prepared 
as an example of functionalization of thienopyridines bearing 
an aniline with an arylisocyanate. The corresponding 3-bromo-
2-(hetero)arylthienopyridines were successfully obtained after 
bromination with bromine. An example of chlorination in the 
pyridine ring was also presented with the synthesis of the 4-
chloro-2-(3-methoxyphenyl)thieno[2,3-b]pyridine, via the 
corresponding N-oxide followed by the reaction with POCl3. 
These thienopyridines may be used as precursors to synthesize 
biologically active compounds. 
 
4. Experimental section 
4.1. General methods: Melting points (oC) were determined in 
a Stuart SMP3 and are uncorrected. 1H and 13C NMR spectra 
were recorded on a Bruker Avance III at 400 and 100.6 MHz 
or on a Varian Unity Plus at 300 and 75.4 MHz, respectively. 
Heteronuclear correlations 1H-13C, HMQC or HSQC and 
HMBC were performed to attribute some signals. Elemental 
analyses were determined on a LECO CHNS 932 elemental 
analyzer. MS-EI, MS-ESI and HRMS on the M+ or on the 
[M++H] data were recorded by the mass spectrometry service 
of the University of Vigo, Spain.  
Column chromatography was performed on Macherey-Nagel 
silica gel 230-400 mesh or on silica-gel. Preparative layer 
chromatography (PLC) was performed on Macherey–Nagel 20 
x 20 cm2 silica plates, layer 2 mm SIL G-200 UV254. Petroleum 
ether refers to the boiling range 40-60 oC. Ether refers to 
diethyl ether. The increase of polarity in solvent gradient was 
made from neat petroleum ether to mixtures of ether/petroleum 
ether, increasing 10% of ether each time until the isolation of 
the products, unless stated otherwise. The most polar products 
were isolated using neat ether, mixtures of ether/ethyl acetate 
or neat ethyl acetate. 
4.2. General experimental conditions for the Sonogashira 
reactions:  
In a dry Schlenk tube, the dihalopyridine, CuI (6 mol%) and 
PdCl2(PPh3)2 (3 mol%) were added in Et3N (2 ml per mmol of 
pyridine). After stirring for 10 minutes, the 
(hetero)arylacetylene (1.0 or 1.1 equiv.) was added, and the 
solution was heated to 100 °C in a silicone bath for 2h. The 
reactions were monitored by TLC, following the disappearance 
of the starting materials. After completion, the mixture was 
allowed to cool to room temperature. Then ethyl acetate and 
water were added and the organic phase was separated, dried 
(MgSO4) and filtered. Removal of the solvent under reduced 
pressure gave either oils which were submitted to column 
chromatography or pure products corresponding to the 
expected (hetero)arylethynyl)pyridines. 
 
4.2 .1 .  2-Chloro -3- (phenylethynyl )pyr id ine (1 )  and 
2 ,3-b is (pheny le thyny l)pyr id ine  
From 3-bromo-2-chloropyridine (192 mg, 1.00 mmol) and 
phenylacetylene (1.1 equiv.) and after purification by column 
chromatography using a solvent gradient from neat petroleum 
ether to 10% ether/petroleum ether,  compound 1 was obtained 
as an yellow solid (170 mg, 80%). Recrystallization from 
ether/petroleum ether gave yellow crystals, m.p. 57-59 ºC. 1H 
NMR (400 MHz, CDCl3): δ = 7.23-7.26 (dd, J = 7.6 and 4.8 
Hz, 1H, 5-H), 7.38-7.40 (m, 3H, Ar-H), 7.58-7.60 (m, 2H, Ar-
H), 7.86 (dd, J = 7.6 and 2.0 Hz, 1H, 4-H), 8.35 (dd, J = 4.8 
and 2.0 Hz, 1H, 6-H) ppm. 13C NMR (100.6 MHz, CDCl3): δ = 
Tetrahedron 6
83.20 (C), 95.82 (C), 119.60 (3-C), 120.85 (5-CH), 121.21 
(C), 127.46 (2 × CH), 128.15 (4´-CH), 130.75 (2 × CH), 
140.17 (4-CH), 147.15 (6-CH), 151.30 (2-C) ppm. MS-EI: m/z 
(%) 215 (M+ 37Cl, 25) 213 (M+ 35Cl, 25). HRMS: Calcd for 
C13H835ClN [M+] 213.0345. Found 213.0346. Calcd for 
C13H837ClN [M+] 215.0316. Found 215.0322. 
In another fraction of the column chromatography eluted 
with 20% ether/petroleum ether, 2,3-bis(2-
phenylethynyl)pyridine was isolated as a brownish oil (17.0 
mg, 6 %). 1H NMR (400 MHz, CDCl3): δ = 7.26 (dd, J = 8.0 
and 5.2 Hz, 1H, 5-H), 7.36-7.39 (m, 6H), 7.58-7.61 (m, 2H), 
7.64-7.66 (m, 2H), 7.87 (dd, J = 8.0 and 1.6 Hz, 1H, 4-H), 8.57 
(dd, J = 5.2 and 1.6 Hz, 1H, 6-H,) ppm. 13C NMR (100.6 MHz, 
CDCl3): 85.84 (C), 87.73 (C), 93.64 (C), 96.17 (C), 122.03 (5-
CH), 122.29 (C), 122.64 (C),123.08 (C), 128.41 (2 × CH), 
128.48 (2 × CH), 128.95 (CH), 129.18 (CH), 131.69 (2 × CH), 
132.16 (2 × CH), 138.96 (4-CH), 144.90 (C), 148.57 (6-CH) 
ppm. MS-EI: m/z (%) 279 (M+, 100). HRMS: Calcd for 
C21H13N [M+] 279.1048. Found 279.1049. 
4.2 .2 .  4-[(2 -Chloropyrid in-3 -y l )e thyny l] ani l ine 
(2 )  
From 3-bromo-2-chloropyridine (144 mg, 0.750 mmol) and 
4-ethynylaniline (1.1 equiv.) and after purification by column 
chromatography using a solvent gradient from 40% 
ether/petroleum ether to 50% ether/petroleum ether,  
compound 2 was obtained as a yellow pale solid (68.0 mg, 
40%). Recrystallization from ether/petroleum ether gave pale 
yellow crystals, m.p. 111-113 ºC. 1H NMR (400 MHz, CDCl3): 
δ = 3.96 (br s, 2H, NH2), 6.65 (d, J = 8.4 Hz, 2H, 3 and 5-H), 
7.21 (dd, J = 7.6 and 4.8 Hz, 1H, 5'-H), 7.39 (d, J = 8.4 Hz, 
2H, 2 and 6-H), 7.81 (dd, J = 7.6 and 2.0 Hz, 1H, 4'-H), 8.29 
(br d, 1H, 6'-H) ppm. 13C NMR (100.6 MHz, CDCl3): δ = 
82.52 (C), 98.03 (C), 111.39 (C), 114.69 (3 and 5-CH), 121.25 
(C), 121.81 (5´-CH), 132.67 (C), 133.22 (2 and 6-CH), 140.72 
(4'-CH), 147.42 (6´-CH), 151.93 (C) ppm. MS-EI: m/z (%) 230 
(M+ 37Cl, 25), 228 (M+ 35Cl, 100). HRMS: Calcd for 
C13H935ClN2 [M+] 228.0454. Found 228.0452. Calcd for 
C13H937ClN2 [M+] 228.0425. Found 228.0435. 
4.2 .3 .  3-[(2 -Chloropyrid in-3 -y l )e thyny] ani l ine (3 )  
   From 3-bromo-2-chloropyridine (150 mg, 0.770 mmol) and 
3-ethynylaniline (1.1 equiv.) and after purification by column 
chromatography using a solvent gradient from 35% 
ether/petroleum ether to 50% ether/petroleum ether,  
compound 3 was obtained as a yellow oil (95.2 mg, 55%). 1H 
NMR (400 MHz, CDCl3): δ = 3.65 (br s, 2H, NH2), 6.70-6.73 
(m, 1H, 6-H), 6.88-6.92 (m, 1H, 2-H), 6.92-6.99 (m, 1H, 4-H), 
7.16 (apparent t, J = 8.0 Hz, 1H, 5-H), 7.23 (dd, J = 8.0 and 4.8 
Hz, 1H, 5’-H), 7.84 (dd, J = 8.0 and 1.6 Hz, 1H, 4’-H), 8.33 
(dd, J = 4.8 and 1.6 Hz, 1H, 6’-H) ppm. 13C NMR (100.6 MHz, 
CDCl3): δ = 83.57 (C), 97.17 (C), 116.15 (6-CH), 117.78 (2-
CH), 120.69 (C), 121.83 (5´-CH), 122.11 (4-CH), 122.83 (C), 
129.39 (5-CH), 141.14 (4'-CH), 146.35 (C), 148.03 (6´-CH), 
152.27 (C) ppm. MS-EI: m/z (%) 230 (M+ 37Cl, 27), 228 (M+ 
35Cl, 100). HRMS: Calcd for C13H935ClN2 [M+] 228.0454. 
Found 228.0449. Calcd for C13H937ClN2 [M+] 230.0425. Found 
230.0430. 
4.2 .4 .  2-[(2 -Chloropyrid in-3 -y l )e thyny l] ani l ine 
(4 )  
From 3-bromo-2-chloropyridine (192 mg, 1.00 mmol) and 
2-ethynylaniline (1.1 equiv.) and after purification by column 
chromatography using a solvent gradient from 50% 
ether/petroleum ether to 60% ether/petroleum ether,  
compound 4 was obtained as a brown solid (116 mg, 50%). 
Recrystallization from ether/petroleum ether gave pale brown 
crystals, m.p. 97-98 ºC. 1H NMR (400MHz, CDCl3): δ = 4.35 
(br s, 2H, NH2), 6.71-6.77 (m, 2H), 7.17-7.22 (m, 1H), 7.25 
(dd, J = 7.6 and 4.8 Hz, 1H, 5'-H), 7.39 (dd, J = 7.6 and 1.2 
Hz, 1H, 5-H), 7.86 (dd, J = 7.6 and 1.8 Hz, 1H, 4'-H), 8.33 (br 
d,1H, 6'-H) ppm. 13C NMR (100.6 MHz, CDCl3): δ = 89.67 
(C), 94.13 (C), 106.60 (C), 114.53 (CH), 117.94 (CH), 120.69 
(C), 121.99 (5´-CH), 130.69 (CH), 132.08 (5-CH), 140.64 (4'-
CH), 147.87 (6´-CH), 148.44 (C), 151.58 (C) ppm. MS-EI: m/z 
(%) 230 (M+ 37Cl, 27), 228 (M+ 35Cl, 100). HRMS: Calcd for 
C13H935ClN2 [M+] 228.0454. Found 228.0450. Calcd for 
C13H937ClN2 [M+] 230.0425. Found 230.0429. 
4.2 .5 .  2-Chloro -3-[ (4 -  
methoxyphenyl )e thyny l] pyr id ine(5 )  
From 3-bromo-2-chloropyridine (150 mg, 0.780 mmol) and 1-
ethynyl-4-methoxybenzene (1.0 equiv) and after purification 
by column chromatography using a solvent gradient from 25% 
ether/petroleum ether to 30% ether/petroleum ether, compound 
5 was obtained a yellow solid (120.0 mg, 65%) m. p. 59-60 ºC. 
1H NMR (400 MHz, CDCl3): δ =  3.85 (s, 3H, OMe), 6.91 (d, J 
=  8.8 Hz, 2H, 3’ and 5’-H), 7.24 (dd, J = 8.0 and 4.8 Hz, 1H, 
5-H), 7.52 (d, J = 8.8 Hz, 2H, 2’ and 6’-H), 7.84 (dd,  J = 8.0 
and 1.6 Hz, 1H, 4-H), 8.32 (dd, J = 4.8 and 1.6 Hz, 1H, 6-H) 
ppm. 13C NMR (100.6 MHz, CDCl3): δ = 55.33 (OMe), 83.05 
(C), 97.25 (C), 114.13 (3’ and 5’-CH), 114.22 (C), 121.05 (C), 
121.88 (5-CH), 133.32 (2’ and 6’-CH), 141.05 (4-CH), 147.57 
(6-CH), 151.94 (C), 160.34 (C) ppm. MS-EI: m/z (%) 245 (M+ 
37Cl, 28), 243 (M+ 35Cl, 100). HRMS: Calcd for C14H1035ClNO 
[M+] 243.0451. Found 243.0450. Calcd for Calcd for 
C14H1037ClNO [M+] 245.0421. Found 245.0427. 
4.2 .6 .  2-Chloro -3-[ (3 -
methoxyphenyl )e thyny l] pyr id ine(6 )  
From 3-bromo-2-chloropyridine (150 mg, 0.780 mmol) and 1-
ethynyl-3-methoxybenzene (1.0 equiv) and after purification 
by column chromatography using a solvent gradient from 25% 
ether/petroleum ether to 30% ether/petroleum ether,  
compound 6 was obtained as a colorless oil  (140 mg, 74%) 1H 
NMR (400 MHz, CDCl3): δ = 3.84 (s, 3H, OMe), 6.94-6.97 
(m, 1H, 4’-H), 7.09-7.11 (m, 1H, 2’-H), 7.17-7.20 (m, 1H, 6’-
H), 7.24 (dd, J = 8.0 and 4.8 Hz, 1H, 5-H), 7.27-7.31 (m, 1H, 
5’-H), 7.86 (dd, J = 8.0 and 1.6 Hz, 1H, 4-H), 8.34 (dd, J = 4.8 
and 1.6 Hz, 1H, 6-H) ppm. 13C NMR (100.6MHz, CDCl3): δ = 
55.32 (OMe), 83.96 (C), 96.73 (C), 115.74 (4’-CH), 116.48 
(2’-CH), 120.53 (C), 121.84 (5-CH), 123.76 (C), 124.31 (6’-
CH), 129.54 (5’-CH), 141.20 (4-CH), 148.18 (6-CH), 152.30 
(C), 159.38 (C) ppm. MS-EI: m/z (%) 245 (M+ 37Cl, 29), 243 
(M+ 35Cl, 100). HRMS: Calcd for C14H1035ClNO [M+] 
243.0451. Found 243.0443. Calcd for C14H1037ClNO [M+] 
245.0421. Found 245.0430. 
4.2 .7 .  2-Chloro -3-[ (2 -
methoxyphenyl )e thyny l] pyr id ine(7 )  
From 3-bromo-2-chloropyridine (150 mg, 0.780 mmol) and 1-
ethynyl-2-methoxybenzene (1.0 equiv) and after purification 
by column chromatography using a solvent gradient from 25% 
ether/petroleum ether to 30% ether/petroleum ether,  
compound 7 was obtained as a colorless oil  (118 mg, 64%) 1H 
NMR (400 MHz, CDCl3): δ = 3.93 (s, 3H, OMe), 6.92-6.99 
(m, 2H), 7.23 (dd, J = 8.0 and 4.8 Hz, 1H, 5-H), 7.34-7.39 (m, 
1H), 7.54 (dd, J = 8.0 and 2.0 Hz, 1H, 6’-H), 7.89 (dd, J = 8.0 
and 1.6 Hz, 1H, 4-H), 8.32 (dd, J = 4.8 and 1.6 Hz, 1H, 6-H) 
ppm. 13C NMR (100.6 MHz, CDCl3): δ = 55.88 (OMe), 88.10 
(C), 93.52 (C), 110.83 (CH), 111.48 (C), 120.54 (CH), 120.92 
(C), 121.76 (5-CH), 130.70 (6’-CH), 133.67 (4-CH), 141.16 
 7 
(C), 147.94 (6-CH), 152.20 (C), 160.25 (C) ppm. MS-EI: m/z 
(%) 245 (M+ 37Cl, 41), 243 (M+ 35Cl, 100). HRMS: Calcd for 
C14H1035ClNO [M+] 243.0451. Found 243.0450. Calcd for 
C14H1037ClNO [M+] 245.0421. Found 245.0415. 
4.2 .8 .  3-[(4 -Bromophenyl )e thynyl] -2-
chloropyr id ine (8 )  
From 3-bromo-2-chloropyridine (150 mg, 0.770 mmol) and 
1-bromo-4-ethynylbenzene (1.0 equiv) and after purification 
by column chromatography using a solvent gradient from 25% 
ether/petroleum ether to 30% ether/petroleum ether,  
compound 8 was obtained a yellow solid (90 mg, 40%), m. p. 
99-100 ºC. 1H NMR (400 MHz, acetone-d6): δ = 7.49-7.51 (m, 
1H, 5-H), 7.67 (d, J = 8.8 Hz, 2H, 2’ and 6’-H),  7.69 (d, J = 
8.8 Hz, 2H, 3’ and 5’-H), 8.09-8.12 (m, 1H, 4-H), 8.44-8.46 
(m, 1H, 6-H) ppm. 13C NMR (100.6 MHz, acetone-d6): δ =  
90.57 (C), 96.54 (C), 120.58 (C), 122.17 (C), 123.56 (5-CH), 
124.06 (C), 132.85 (2’ and 6’-CH), 134.17 (3’ and 5’-CH), 
142.57 (4-CH), 149.87 (6-CH), 152.39(C) ppm. MS-ESI: m/z 
(%) 296 (M+ 81Br37Cl+H, 25), 294 (M+ 81Br35Cl or 79Br37Cl +H, 
100), 292 (M+79Br35Cl+H, 81). HRMS: Calcd for 
C13H779Br35ClN [M++H] 291.9529. Found 291.9524. Calcd for 
C13H781Br35ClN [M++H] 293.9502. Found 293.9502. Calcd for 
C13H779Br37ClN [M++H] 293.9499. Found 293.9502. Calcd for 
C13H781Br37ClN [M+ +H]  295.9479. Found 295.9478. 
4.2 .9 .  2-Chloro -3-[ (3 -
f luoropheny l)ethynyl] pyr id ine (9 )  
From 3-bromo-2-chloropyridine (100 mg, 0.530 mmol) and 
1-ethynyl-3-fluorobenzene (1.0 equiv) and after purification by 
column chromatography using a solvent gradient from 25%  
ether/petroleum ether to 30% ether/petroleum ether,  
compound 9 was obtained as a colourless oil (80.0 mg, 70 %). 
1H NMR (400 MHz, CDCl3): δ = 7.08-7.13 (m, 1H), 7.24-7.28 
(m, 2H), 7.35-7.37 (m, 2H), 7.87 (dd, J = 8.0 and 1.6 Hz, 1H, 
4-H), 8.37 (dd, J = 4.8 and 1.6 Hz, 1H, 6-H) ppm. 13C NMR 
(100.6 MHz, CDCl3): δ = 84.93 (C), 95.34 (d, J = 4.0 Hz, C), 
116.53 (d, J = 21.1 Hz, CH), 118.51 (d, J = 23.1 Hz, CH), 
120.17 (C), 121.88 (5-CH), 124.00 (d, J = 10.1 Hz, 1’-C), 
127.66 (d, J = 3.0 Hz, 6’- CH), 130.10 (d, J = 9.1 Hz, 5’-CH), 
141.29 (4-CH), 148.48 (6-CH), 152.37 (C), 162.35 (d, J = 
247.5 Hz, CF) ppm. MS-EI: m/z (%) 233 (M+ 37Cl, 36), 231 
(M+ 35Cl, 100). HRMS: Calcd for C13H735ClFN [M+] 231.0251. 
Found 231.0259. Calcd for C13H737ClFN [M+] 233.0222. 
Found 233.0230. 
4.2 .10 .  2-Chloro -3-[ ( th iophen-3-
yl )e thynyl] pyr id ine (10 )  
From 3-bromo-2-chloropyridine (150 mg, 0.770 mmol) and 
3-ethynylthiophene (1.1 equiv) and after purification by 
column chromatography using 30% ether/petroleum ether, 
compound 10 was obtained  as a colorless oil (117 mg, 70%). 
1H NMR (400 MHz, CDCl3): δ = 7.23-7.25 (m, 2H), 7.33-7.35 
(m, 1H), 7.62-7.65 (m, 1H), 7.85 (dd, J = 8.0 and 2.0 Hz, 1H, 
4-H), 8.34 (dd, J = 4.8 and 2.0 Hz, 1H, 6-H) ppm. 13C NMR 
(100.6 MHz, CDCl3): δ = 83.77 (C), 92.05 (C), 120.61 (C), 
121.29 (C), 121.84 (CH), 125.72 (CH), 129.72 (CH), 129.95 
(CH),  141.14 (4-CH), 148.05 (6-CH), 152.12 (C) ppm. MS-
ESI: m/z (%) 222 (M+ 37Cl+H, 40), 220 (M+ 35Cl+H, 100)  
HRMS: Calcd for C11H7ClNS [M+ 35Cl] 219.9988. Found 
219.9993. Calcd for C11H7ClNS [M+ 37Cl] 221.9958. Found 
221.9952. 
4.2 .11 .  2-Chloro -3- (pyr id in -3-ylethynyl )pyr id ine 
(11 )  
From 3-bromo-2-chloropyridine (192 mg, 1.00 mmol) and 
3-ethynylpyridine (1.1 equiv.) and after purification by column 
chromatography using a solvent gradient from 40% 
ether/petroleum ether to 50% ether/petroleum ether,  
compound 11 was obtained as a white-off solid (130 mg, 
60%). Recrystallization from ether/petroleum ether gave off-
white crystals, m.p. 64-66 ºC. 1H NMR (400 MHz, CDCl3): δ = 
7.24-7.27 (dd, J = 7.6 and 4.8 Hz, 1H, 5-H), 7.31-7.34 (m, 1H), 
7.85-7.88 (m, 2H), 8.37 (dd, J = 4.8 and 1.6 Hz, 1H, 6-H), 8.60 
(dd, J = 5.2 and 1.6 Hz, 1H, 6’-H), 8.81 (br s, 1H, 2’-H) ppm. 
13C NMR (100.6 MHz, CDCl3): 87.33 (C), 93.10 (C), 119.51 
(C), 119.85 (C), 121.89 (5-CH), 123.16 (CH), 138.68 (CH), 
141.30 (CH), 148.72 (6-CH), 149.21 (6’-CH), 152.11 (2’-CH), 
152.33 (C) ppm. Anal. Calcd for C12H7ClN2 (214.65): C, 
67.15; H, 3.29; N, 13.05. Found: C, 66.99; H, 3.42; N, 12.76. 
4.2 .12 .  2-Chloro -3- (pyr id in -2-ylethynyl )pyr id ine 
(12 )  
From 3-bromo-2-chloropyridine (150.0 mg, 0.770 mmol) 
and 2-ethynylpyridine (1.0 equiv) and after purification by 
column chromatography using a solvent gradient from 35% 
ether/petroleum ether to 40% ether/petroleum ether,  
compound 12 was obtained as a colorless oil  (83.0 mg, 50%) 
1H NMR (400 MHz, acetone-d6): δ = 7.46-7.49 (m, 1H), 7.53 
(dd, J = 8.0 and 4.8 Hz, 1H, 5-H), 7.70-7.73 (m, 1H), 7.89-7.93 
(m, 1H), 8.16 (dd, J = 8.0 and 2.0 Hz, 1H, 4-H), 8.48 (dd, J = 
4.8 and 2.0 Hz, 1H, 6-H) 8.68-8.70 (m, 1H, 3’-H) ppm. 13C 
NMR (100.6 MHz, acetone-d6): δ = 83.62 (C), 96.44 (C), 
120.19 (C), 123.57 (5-CH), 124.72 (CH), 128.48 (CH), 137.39 
(CH), 143.03 (4-CH), 143.28 (C), 150.24 (6-CH), 151.23 (6’-
CH) 152.62 (C) ppm. MS-EI: m/z (%) 216 (M+ 37Cl, 29), 214 
(M+ 35Cl, 100). HRMS: Calcd for C12H735ClN2 [M+] 214.0298. 
Found 214.0297. Calcd for C12H737ClN2 [M+] 216.0268. Found 
216.0274. 
4.2 .13 .  2-Chloro -3-[ (1 -methy l -1H- imidazo l-5 -
yl )e thynyl] pyr id ine (13 )  
From 3-bromo-2-chloropyridine (192 mg, 1.00 mmol) and 
5-ethynyl-1-methyl-1H-imidazole (1.1 equiv.) and after 
purification by column chromatography using neat ethyl 
acetate as the solvent, compound 13 was obtained as an off-
white solid (116 mg, 55%). Recrystallization from 
ether/petroleum ether gave yellow crystals, m.p. 120-122 ºC. 
1H NMR (300 MHz, DMSO-d6): δ = 3.74 (s, 3H, NMe), 7.42 
(br s, 1H), 7.50 (dd, J = 7.8 and 4.8 Hz, 1H, 5-H), 7.86 (br s, 
1H), 8.17 (dd, J = 7.8 and 2.0 Hz, 1H, 4-H), 8.42 (dd, J = 4.8 
and 2.0 Hz, 1H, 6-H) ppm. 13C NMR (75.4 MHz, DMSO-d6): δ 
= 30.65 (NMe), 85.38 (C), 91.09 (C), 118.98 (C), 123.06 (5-
CH), 135.63 (C), 141.46 (4-CH), 149.01 (6-CH), 150.11 (C) 
ppm. MS-ESI: m/z (%) 220 (M+ 37Cl+H, 37), 218 (M+ 35Cl+H, 
100). HRMS: Calcd for C11H935ClN3 [M++H] 218.0480. Found 
218.0472. Calcd for C11H937ClN3 [M++H] 220.0455. Found 
220.0451. 
4.2 .14 .  3-Chloro -2- (phenylethynyl )pyr id ine (14 )  
From 2-bromo-3-chloropyridine (96.0 mg, 0.500 mmol) and 
phenylacetylene (1.1 equiv.) and after purification by column 
chromatography using a solvent gradient from neat petroleum 
ether to 20% ether/petroleum ether, compound 14 was obtained 
as a yellow solid (94.0 mg, 88%). Recrystallization from 
ether/petroleum ether gave yellow crystals, m.p. 48-50 ºC. 1H 
NMR (400 MHz, CDCl3): δ = 7.22 (dd, J = 8.0 and 4.8 Hz, 1H, 
5-H), 7.37-7.41 (m, 3H, 3´, 4´and 5´-H), 7.64-7.67 (m, 2H, 
2´and 6´-H), 7.77 (dd, J = 8.0 and 1.6 Hz, 1H, 4-H), 8.52 (br d, 
1H, 6-H) ppm. 13C NMR (100.6 MHz, CDCl3): δ = 85.78 (C), 
94.83 (C), 121.91 (C), 123.36 (5-CH), 128.41 (3´and 5´-CH), 
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129.37 (4´-CH), 132.20 (2´and 6´-CH), 134.14 (C), 136.72 
(4-CH), 142.04 (C), 147.70 (6-CH) ppm. Anal. Calcd for 
C13H8ClN (213.66): C, 73.08; H, 3.77; N, 6.56. Found: C, 
72.77; H, 3.80; N, 6.59.  
4.2 .15 .  4-[(3 -Chloropyrid in-2 -y l )e thyny l] ani l ine 
(15 )  
From 2-bromo-3-chloropyridine (96.0 mg, 0.500 mmol) and 
4-ethynylaniline (1.1 equiv.) and after purification by column 
chromatography using a solvent gradient from 50% 
ether/petroleum ether to 70% ether/petroleum ether, compound 
15 was obtained as an orange solid (80.0 mg, 70%). 
Recrystallization from ether/petroleum ether gave yellow 
crystals, m.p. 161-163 ºC. 1H NMR (400 MHz, CDCl3): δ = 
3.92 (br s, 2H, NH2), 6.65 (d, J = 8.4 Hz, 2H, 2- and 6-H), 7.15 
(dd, J = 8.2 and 4.6 Hz, 1H, 5'-H), 7.45 (d, J = 8.4 Hz, 2H, 3- 
and 5-H), 7.73 (dd, J = 8.2 and 1.4 Hz, 1H, 4'-H), 8.48 (dd, J = 
4.6 and 1.4 Hz, 1H, 6'-H) ppm. 13C NMR (100.6 MHz, CDCl3): 
δ = 84.47 (C), 96.29 (C), 111.00 (C), 114.59 (2 and 6-CH), 
122.63 (5´-CH), 133.50 (C), 133.78 (3 and 5-CH), 136.50 (4´-
CH), 142.66 (C), 147.64 (6´-CH), 147.68 (C) ppm. MS-EI: m/z 
(%) 230 (M+ 37Cl, 30), 228 (M+ 35Cl, 100). HRMS: Calcd for 
C13H935ClN2 [M+] 228.0454. Found 228.0462. Calcd for 
C13H937ClN2 [M+] 230.0425. Found 230.0434. 
 
4.2 .16 .  3-[(3 -Chloropyrid in-2 -y l )e thyny l] ani l ine 
(16 )  
From 2-bromo-3-chloropyridine (96.0 mg, 0.500 mmol) and 
3-ethynylaniline (1.1 equiv.) and after purification by column 
chromatography using a solvent gradient from 50% 
ether/petroleum ether to 70% ether/petroleum ether, compound 
16 was obtained as a beige solid (95.0 mg, 83%). 
Recrystallization from ether/petroleum ether gave beige 
crystals, m.p. 109-111 ºC. 1H NMR (400MHz, CDCl3): δ = 
3.16 (br s, 2H, NH2), 6.72 (br d, 1H), 6.96 (br s, 1H, 2-H), 7.05 
(br d, 1H), 7.14-7.22 (m, 2H, 5'-H and ArH), 7.75 (dd, J = 8.2 
and 1.4 Hz, 1H, 4'-H), 8.51 (br d, 1H, 6'-H) ppm. 13C NMR 
(100.6 MHz, CDCl3): δ = 85.26 (C), 95.12 (C), 116.43 (CH), 
118.28 (2-CH), 122.56 (C), 122.69 (CH), 123.27 (5´-CH), 
129.34 (CH), 134.13 (C), 136.64 (4´-CH), 142.16 (C), 146.21 
(C), 147.72 (6´-CH) ppm. MS-EI: m/z (%) = 230 (M+ 37Cl, 30), 
228 (M+ 35Cl, 100). HRMS: Calcd for C13H935ClN2 [M+] 
228.0454. Found 228.0457 [M+]. Calcd for C13H937ClN2 [M+] 
230.0425. Found 230.0434. 
4.2 .17 .  2-[(3 -Chloropyrid in-2 -y l )e thyny l] ani l ine 
(17 )  
From 2-bromo-3-chloropyridine (120 mg, 0.624 mmol) and 
2-ethynylaniline (80.0 mg, 0.687 mmol) and after purification 
by column chromatography using a solvent gradient from 50% 
ether/petroleum ether to 70% ether/petroleum ether, compound 
17 was obtained as a yellow solid (126 mg, 89%). 
Recrystallization from ether/petroleum ether gave beige 
crystals, m.p. 111-112 ºC. 1H NMR (400 MHz, DMSO-d6): δ = 
5.53 (br s, 2H, NH2), 6.57-6.61 (m, 1H, 4-H), 6.77-6.80 (m, 
1H, 6-H), 7.15-7.19 (m, 1H, 5-H), 7.28-7.32 (m, 1H, 3-H), 
7.42 (dd, J = 8.0 and 4.8 Hz, 1H, 5’-H), 8.05 (dd, J = 8.0 and 
1.6 Hz, 1H, 4’-H), 8.55 (dd, J = 4.8 and 1.6 Hz, 1H, 6’-H) . 13C 
NMR (100.6 MHz, DMSO-d6): δ = 91.03 (C), 91.95 (C), 
103.79 (C), 114.17 (6-CH), 116.17 (4-CH), 124.18 (5´-CH), 
131.11 (5-CH), 132.03 (3-CH), 132.33 (C), 137.00 (4’-CH), 
140.99 (C), 148.38 (6´-CH), 150.27 (C). MS-EI: m/z (%) 230 
(M+ 37Cl, 27), 228 (M+ 35Cl, 100). HRMS: Calcd for 
C13H935ClN2 [M+] 228.0454. Found 228.0465 [M+]. Calcd for 
C13H937ClN2 [M+] 230.0425. Found 230.0436. 
4.2 .18 .  3-Chloro -2-[ (4 -
methoxyphenyl )e thyny] pyr id ine (18 )  
From 2-bromo-3-chloropyridine (100 mg, 0.530 mmol) and 1-
ethynyl-4-methoxybenzene (1.0 equiv), compound 18 was 
obtained a yellow solid (114.0 mg, 90%). Recrystallization 
from ether/petroleum ether gave beige crystals, m.p. 64-65ºC. 
1H NMR (400 MHz, CDCl3): δ =  3.83 (s, 3H, OMe), 6.90 (d, J 
= 8.8 Hz, 2H, 3’ and 5’-H), 7.21-7.22 (m, 1H, 5-H), 7.59 (d, J 
= 8.8 Hz, 2H, 2’ and 6’-H), 8.73-8.77 (m, 1H, 4-H), 8.50-8.54 
(m, 1H, 6-H) ppm. 13C NMR (100.6 MHz, CDCl3): δ = 55.29 
(OMe), 84.87 (C), 95.56 (C), 113.85 (C), 114.08 (3’ and 5’-
CH), 123.04 (5-CH), 133.81 (2’ and 6’-CH), 133.97 (C), 
136.68 (4-CH), 142.23 (C), 147.47 (6-CH), 160.53 (C) ppm. 
MS-EI: m/z (%) 245 (M+ 37Cl, 29), 243 (M+ 35Cl, 100). HRMS: 
Calcd for C14H1035ClNO [M+] 243.0451. Found 243.0449. 
Calcd for C14H1037ClNO [M+] 245.0421. Found 245.0427. 
4.2 .19 .  3-Chloro -2-[ (3 -
methoxyphenyl )e thyny l] pyr id ine (19 )  
From 2-bromo-3-chloropyridine (100 mg, 0.530 mmol) and 1-
ethynyl-3-methoxybenzene (1.0 equiv.) compound 19 was 
obtained as oil  (120.0 mg, 92%). 1H NMR (400 MHz, CDCl3): 
δ =  3.79 (s, 3H, OMe), 6.91-6.94 (m, 1H), 7.14-7.25 (m, 4H), 
7.71 (dd, J = 8.2 and 1.2 Hz, 1H, 4-H), 8.50 (dd, J = 4.8 and 
1.2 Hz, 1H, 6-H) ppm. 13C NMR (100.6 MHz, CDCl3): δ = 
55.20 (OMe), 85.44 (C), 94.83 (C), 116.04 (CH), 116.64 (CH), 
122.68 (C), 123.34 (CH), 124.50 (CH), 129.37 (CH), 134.03 
(C), 136.60 (4-CH), 141.79 (C), 147.76 (6-CH), 159.19 (C)  
ppm. MS-EI: m/z (%) 245 (M+ 37Cl, 31), 243 (M+ 35Cl, 100). 
HRMS: Calcd for C14H1035ClNO [M+] 243.0451. Found 
243.0454. Calcd for C14H1037ClNO [M+] 245.0421. Found 
245.0428. 
4.2 .20 .  3-Chloro -2-[ (2 -
methoxyphenyl )e thyny l] pyr id ine (20 )  
From 2-bromo-3-chloropyridine (100 mg, 0.530 mmol) and 1-
ethynyl-2-methoxybenzene (1.0 equiv), compound 20 was 
obtained as oil  (118.0 mg, 90%) 1H NMR (400 MHz, CDCl3): 
δ =  3.89 (s, 3H, OMe), 6.88-6.95 (m, 2H), 7.17 (dd, J = 8.4 
and 4.8 Hz, 1H, 5-H), 7.31-7.36 (m, 1H), 7.56-7.58 (m, 1H), 
7.70-7.73 (m, 1H), 7.50 (dd, J = 4.8 and 1.6 Hz, 1H, 6-H) ppm. 
13C NMR (100.6 MHz, CDCl3): δ = 55.77 (OMe), 89.60 (C), 
91.80 (C), 110.72 (CH), 111.03 (C), 120.35 (CH), 123.12 (5-
CH), 130.91 (CH), 133.88 (C), 133.94 (CH), 136.62 (CH), 
142.11 (C), 147.59 (6-CH), 160.59 (C) ppm. MS-EI: m/z (%) 
245 (M+ 37Cl, 40), 243 (M+ 35Cl, 100). HRMS: Calcd for 
C14H1035ClNO [M+] 243.0451. Found 243.0459. Calcd for 
C14H1037ClNO [M+] 245.0421. Found 245.0429. 
4.2 .21 .  2-[(4 -Bromophenyl )e thynyl] -3-
chloropyr id ine (21 )  
From 2-bromo-3-chloropyridine (150 mg, 0.770 mmol) and 
1-bromo-4-ethynylbenzene (1.0 equiv) and after purification 
by column chromatography using a solvent gradient from 25% 
ether/petroleum ether to 30% ether/petroleum ether,  
compound 21 was obtained a brown solid (192 mg, 85  %),  m. 
p. 71-72ºC. 1H NMR (400 MHz, acetone-d6): δ = 7.47 (dd, J = 
8.2 and 4.4 Hz, 1H, 5-H), 7.65 (d, J = 8.4 Hz, 2H, 2’ and 6’-
H), 7.70 (d, J = 8.4 Hz, 2H, 3’ and 5’-H), 8.00 (dd, J =  8.2 and 
1.6 Hz, 1H, 4-H), 8.60 (dd, J =  4.8 and 1.6 Hz, 1H, 6-H) ppm. 
13C NMR (100.6 MHz, acetone-d6): δ = 87.83 (C), 93.21 (C), 
121.85 (C), 124.31 (C), 125.29 (5-CH), 132.87 (3’ and 5’-CH), 
134.43 (2’ and 6’-CH), 134.57 (C), 137.70 (4-CH), 142.07 (C), 
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149.16 (6-CH) ppm. Anal. Calcd for C13H7BrClN (292.56): C, 
53.37; H, 2.41; N, 4.79. Found: C, 53.04; H, 2.62; N, 4.74. 
4.2 .22 .  3-Chloro -2-[ (3 -
f luoropheny l)ethynyl] pyr id ine (22 )  
From 2-bromo-3-chloropyridine (60.0 mg, 0.300 mmol) and 
1-ethynyl-3-fluorobenzene (1.0 equiv) and after purification by 
column chromatography using a solvent gradient from 25% 
ether/petroleum ether to 30% ether/petroleum ether,  
compound 22 was obtained as an oil (40.0 mg, 60 %). 1H NMR 
(400MHz, CDCl3): δ = 7.08-7.14 (m, 1H), 7.24 (dd, J = 8.0 
and 4.8 Hz, 1H, 5-H), 7.31-7.38 (m, 2H), 7.42-7.44 (m, 1H), 
7.77 (dd, J = 8.0 and 1.6 Hz, 1H, 4-H), 8.53 (dd, J = 4.8 and 
1.6 Hz, 1H, 6-H) ppm. 13C NMR (100.6 MHz, CDCl3): δ =  
86.38 (C), 93.19 (d, J = 3.0 Hz, C), 116.82 (d, J = 21.1 Hz, 
CH), 118.89 (d, J = 23.0 Hz, CH), 123.66 (5-CH), 128.09 (d, J 
= 3.0 Hz, 6’-CH), 130.04 (d, J = 6.0 Hz, 5’-CH), 130.13 (d, J = 
6.0 Hz, C) 134.33 (C), 136.80 (4-CH), 141.60 (C), 147.76 (6-
CH), 162.29 (d, J = 247.5 Hz, CF) ppm. MS-EI: m/z (%) 233 
(M+ 37Cl, 33), 231 (M+ 35Cl, 100). HRMS: Calcd for C13H7ClFN 
[M+ 35Cl] 231.0251. Found 231.0243. Calcd for C13H7ClFN [M+ 
37Cl] 233.0222. Found 233.0223. 
4.2 .23 .  3-Chloro -2-[ ( th iophen-3-
yl )e thynyl] pyr id ine (23 )  
From 2-bromo-3-chloropyridine (150 mg, 0,770 mmol) and 
3-ethynylthiophene (1.1 equiv) and after purification by 
column chromatography using 30% ether/petroleum ether, 
compound 23 was obtained as an oil (130.7 mg, 70%). 1H 
NMR (400 MHz, CDCl3): δ = 7.23 (dd, J = 8.2 and 4.8 Hz, 1H, 
5-H) 7.28-7.35 (m, 1H,), 7.32-7.34 (m, 1H), 7.69-7.74 (m, 1H), 
7.78 (dd, J = 8.2 and 1.6 Hz, 1H, 4-H), 8.52 (dd, J = 4.8 and 
1.6 Hz, 1H, 6-H)  ppm. 13C NMR (100.6 MHz, CDCl3): δ = 
85.13 (C), 90.86 (C), 120.91 (C), 123.31 (5-CH), 125.65 (CH), 
130.01 (CH), 131.13 (CH), 134.02 (C),  137.11 (4-CH), 141.70 
(C), 147.29 (6-CH) ppm. MS-ESI: m/z (%) 222 [M+ 37Cl+H, 
40], 220 [M+ 35Cl+H, 100]. HRMS: Calcd for C11H735ClNS 
[M+] 219.9982, found 219.9982. Calcd for C11H737ClNS [M+] 
221.9958, found 221.9953. 
4.2 .24 .  3-Chloro -2- (pyr id in -3-ylethynyl )pyr id ine 
(24 )  
From 2-bromo-3-chloropyridine (96.0 mg, 0.500 mmol) and 
3-ethynylpyridine (1.1 equiv.) and after purification by column 
chromatography using a solvent gradient from 50% 
ether/petroleum ether to 70% ether/petroleum ether, compound 
24 was obtained as an off-white solid (93.0 mg, 87%). 
Recrystallization from ether/petroleum ether gave off-white 
crystals, m.p. 58-60 ºC. 1H NMR (400MHz, CDCl3): δ = 7.23 
(dd, J = 8.2 and 4.6 Hz, 1H, 5-H), 7.29-7.33 (m, 1H, 5’-H), 
7.76 (dd, J = 8.2 and 1.2 Hz, 1H, 4-H), 7.89-7.92 (m, 1H, 4’-
H), 8.51 (dd, J = 4.6 and 1.2 Hz, 1H, 6-H), 8.59 (dd, J = 5.0 
and 1.6 Hz, 1H, 6’-H), 8.85 (br s, 1H,  2’-H) ppm. 13C NMR 
(100.6 MHz, CDCl3): δ = 88.75 (C), 90.75 (C), 119.17 (C), 
123.07 (5’-CH), 123.84 (5-CH), 134.26 (C), 136.75 (4-CH), 
139.00 (4’-CH), 141.36 (C), 147.86 (6-CH), 149.40 (6’-CH), 
152.52 (2’-CH) ppm. Anal. Calcd for C12H7ClN2 (214.65): C, 
67.15; H, 3.29; N, 13.05. Found: C, 66.85; H,3.46; N, 12.74. 
 
4.2 .25 .  3-Chloro -2- (pyr id in -2-ylethynyl )pyr id ine 
(25 )  
From 2-bromo-3-chloropyridine (96.0 mg, 0.500 mmol) and 
2-ethynylpyridine (1.1 equiv.) and after purification by column 
chromatography using a solvent gradient from 50% 
ether/petroleum ether to 100% ether,  compound 25 was 
obtained as an off-white solid (100 mg, 93%). 
Recrystallization from ether/petroleum ether gave yellow 
crystals, m.p. 57-59 ºC. 1H NMR (400 MHz, CDCl3): δ = 7.25 
(dd, J = 8.0 and 4.8 Hz, 1H, 5-H), 7.29-7.31 (m, 1H), 7.64 (br 
d, 1H), 7.69-7.73 (m, 1H), 7.75-7.77 (m, 1H), 8.52 (br d, 1H, 
H), 8.67 (br s, 1H) ppm. 13C NMR (100.6 MHz, CDCl3): δ = 
84.40 (C), 92.80 (C), 123.58 (CH), 123.96 (5-CH), 127.93 
(CH), 134.67 (C), 136.15 (CH), 136.73 (4-CH), 141.29 (C), 
142.31 (C), 147.84 (CH), 150.24 (CH) ppm. MS-EI: m/z (%) 
216 (M+ 37Cl, 34), 214 (M+ 35Cl, 100), 179 (M+-35, 60). HRMS: 
Calcd for C12H735ClN2 [M+] 214.0298, found 214.0301. Calcd 
for C12H737ClN2 [M+] 216.0268, found 216.0277. 
4.2 .26 .  3-Chloro -2-[2 - (1-methyl -1H-imidazo l-5 -
yl )e thynyl] pyr id ine (26 )  
From 2-bromo-3-chloropyridine (96.0 mg, 0.500 mmol) and 
5-ethynyl-1-methyl-1H-imidazole (1.1 equiv.) and after 
purification by column chromatography using neat ethyl 
acetate, compound 26 was obtained as a yellow solid (86.0 mg, 
80%). Recrystallization from ether/petroleum ether gave 
yellow crystals, m.p. 149-151 ºC. 1H NMR (400 MHz,DMSO-
d6): δ = 3.78 (s, 3H, NMe), 7.47 (dd, J = 8.2 and 4.6 Hz, 1H, 5-
H), 7.64 (br s, 1H), 8.07 (dd, J = 8.2 and 1.4 Hz, 1H, 4-H), 
8.11 (br s, 1H), 8.56 (dd, J = 4.6 and 1.4 Hz, 1H, 6-H) ppm. 
13C NMR (100.6MHz, DMSO-d6): δ = 32.40 (NMe), 81.97 
(C), 93.16 (C), 114.89 (C), 124.83 (5-CH), 132.59 (C), 134.38 
(CH), 137.23 (4-CH), 140.18 (C), 140.53 (CH), 148.57 (6-CH) 
ppm. MS-ESI: m/z (%) 220 (M+ 37Cl+ H, 37), 218 (M+ 35Cl+H, 
100). HRMS: Calcd for C11H935ClN3 [M++H] 218.0479. Found 
218.0475. Calcd for C11H937ClN3 [M++H] 220.0455. Found 
220.0437. 
4.3. General conditions for the synthesis of thienopyridines: 
Two-pots: A suspension of the (hetero)arylethynylpyridines 
with Na2S (4.0 equiv.) in DMF was stirred in an oil bath at 130 
ºC overnight. Then the mixture was diluted with H2O and 
extracted three times with ethyl acetate. The combined organic 
layers were washed with brine, dried over anhydrous MgSO4, 
filtered, and concentrated to dryness under reduced pressure, 
affording the expected thienopyridines as solids. 
One-pot: the Sonogashira reaction was performed according to 
4.2. After completion, Na2S (4.0 equiv.) in DMF was added 
and the mixture was heated at 130ºC during 2h. After workup 
(described in 4.3) the crude product was purified by 
recrystallization or dry flash chromatography. 
4.3 .1 .   2-Pheny l th ieno[2 ,3-b] pyr id ine (27 )  
From compound 1 (91.0 mg, 0.426 mmol), compound 27 
was obtained as an orange solid (81.0 mg, 90%). 
Recrystallization from ether/petroleum ether gave orange 
crystals, m.p. 88-90 ºC. 1H NMR (400 MHz, CDCl3): δ = 7.29 
(dd, J = 8.0 and 4.8 Hz 1H, 5-H), 7.36-7.41 (m, 1H), 7.44-7.48 
(m, 3H), 7.73 (m, 2H), 8.02 (dd, J = 8.0 and 1.6 Hz, 1H, 4-H), 
8.53 (br d, 1H, 6-H) ppm. 13C NMR (100.6 MHz, CDCl3): δ = 
116.62 (CH), 119.79 (5-CH), 126.56 (2×CH), 128.80 (CH), 
129.03 (2×CH), 130.66 (4-CH), 133.81 (C), 134.24 (C), 144.55 
(C), 146.24 (6-CH), 161.46 (C) ppm. MS-EI: m/z (%) = 211 
(M+, 100). HRMS: Calcd for C13H9NS [M+] 211.0456. Found 
211.0458. 
In one-pot, from 3-bromo-2-chloropyridine (70.0 mg, 0.364 
mmol) and phenylacetylene (1.1 equiv.) and after purification 
by dry flash chromatography using a solvent gradient from 
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compound 27 was obtained as an orange solid (65.0 mg, 85%). 
4.3 .2 .  4-(Thieno[2 ,3 -b] pyr id in-2-yl )ani l ine (28 )  
From compound 2 (50.0 mg, 0.220 mmol), compound 28 
was obtained as a yellow oil (45.0 mg, 91%). 1H NMR (400 
MHz, CDCl3): δ = 3.65 (br s, 2H, NH2), 6.60 (d, J = 8.4 Hz, 
2H, 2 and 6-H), 6.97 (dd, J = 8.0 and 4.8 Hz, 1H, 5’-H), 7.03 
(s, 1H, 3’-H), 7.23 (d, J = 8.4 Hz, 2H, 3 and 5-H), 7.68 (dd, J = 
8.0 and 1.6 Hz, 1H, 4’-H), 8.12 (dd, J = 4.8 and 1.6 Hz, 1H, 6’-
H) ppm. 13C NMR (100.6 MHz, CDCl3): δ = 113.82 (3’-CH), 
116.12 (2 and 6-CH), 119.09 (5’-CH), 124.30 (C), 126.78 (3 
and 5-CH), 129.45 (4’-CH), 133.81 (C), 143.88 (C), 144.16 
(C), 144.73 (6’-CH), 159.97 (C) ppm. MS-EI: m/z (%) 226 
(M+, 100). HRMS: Calcd. for C13H10N2S [M+] 226.0565. 
Found 226.0567. 
In one-pot, from 3-bromo-2-chloropyridine (65.0 mg, 0.338 
mmol) and 4-ethynylaniline (1.1 equiv.) and after purification 
by dry flash chromatography using a solvent gradient from 
40% ether/petroleum ether to 60% ether/petroleum ether, 
compound 25 was obtained as a beige solid (31.0 mg, 40%). 
4.3 .3 .  3-(Thieno[2 ,3 -b] pyr id in-2-yl )ani l ine (29 )  
From compound 3 (50.0 mg, 0.220 mmol), compound 29 
was obtained as a yellow solid  (45.0 mg, 96%), m.p. 145-146 
ºC. 1H NMR (400 MHz, DMSO-d6): δ = 5.47 (br s, 2H, NH2), 
6.61-6.64 (br d, 1H, 6-H), 6.96-6.98 (m, 2H, 2 and 4-H), 7.11-
7.15 (m, 1H, 5-H), 7.41 (dd, J = 8.0 and 4.8 Hz, 1H, 5’-H), 
7.67 (s, 1H, 3’-H), 8.20 (dd, J = 8.0 and 1.6 Hz,1H, 4’-H), 8.50 
(dd, J = 4.8 and 1.6 Hz, 1H, 6’-H) ppm. 13C NMR (100.6 MHz, 
DMSO-d6): δ = 111.49 (2-CH), 113.88 (4-CH), 114.87 (6-CH), 
116.90 (3’-CH), 120.30 (5’-CH), 129.77 (5-CH), 131.18 (4’-
CH), 133.59 (C), 133.97 (C), 143.96 (C), 146.32 (6’-CH), 
149.02 (C), 160.15 (C) ppm. MS-EI: m/z (%) 226 (M+, 100). 
HRMS: Calcd. for C13H10N2S [M+] 226.0565. Found 226.0567. 
4.3 .4 .  2-(Thieno[2 ,3 -b] pyr id in-2-yl )ani l ine (30 )  
From compound 4 (100 mg, 0.430 mmol), compound 30 
was obtained as a brownish oil (80.0 mg, 82%). 1H NMR (400 
MHz, DMSO-d6): δ = 5.53 (br s, 2H, NH2), 6.66 (dt, J = 7.6 
and 1.2 Hz, 1H, 4-H), 6.84 (dd, J = 7.6 and 1.2 Hz, 1H, 6-H), 
7.11 (dt, J = 7.6 and 1.2 Hz, 1H, 5-H), 7.26 (dd, J = 7.6 and 1.2 
Hz, 1H, 3-H), 7.41 (dd, J = 8.2 and 4.8 Hz, 1H, 5’-H), 7.54 (s, 
1H, 3’-H), 8.19 (dd, J = 8.2 and 1.6 Hz, 1H, 4’-H), 8.51 (dd, J 
= 4.8 and 1.6 Hz, 1H, 6’-H) ppm. 13C NMR (100.6 MHz, 
DMSO-d6): δ = 116.10 (6-CH), 116.74 (4-CH), 117.41 (C), 
119.76 (3’-CH), 120.05 (5’-CH), 129.62 (5-CH), 130.36 (3-
CH), 131.01 (4’-CH), 133.76 (C), 141.51 (C), 146.00 (C), 
146.08 (6’-CH), 160.40 (C) ppm. MS-EI: m/z (%) 226 (M+, 
100). HRMS: Calcd. for C13H10N2S [M+] 226.0565. Found 
226.0566. 
 
In one-pot, from 3-bromo-2-chloropyridine (65.0 mg, 0.338 
mmol) and 2-ethynylaniline (1.1 equiv.) and after purification 
by dry flash chromatography using a solvent gradient from 
40% ether/petroleum ether to 60% ether/petroleum ether, 
compound 27 was obtained as a beige solid (35.0 mg, 45%). 
 
4.3 .5 .  2-(4 -Methoxyphenyl ) th ieno[2 ,3-b] pyr id ine 
(31 )  
From compound 5  (62.0 mg, 0.250 mmol), compound 31 
was obtained as a yellow  solid, (55.0 mg, 91%),  m.p. 119-120 
ºC. 1H NMR (400 MHz, CDCl3): δ = 3.86 (s, 3H, OMe), 6.97 
(d, J = 8.8 Hz, 2H, 3’ and 5’-H), 7.28 (dd, J = 8.0 and 4.8 Hz, 
1H, 5-H), 7.34 (s, 1H, 3-H), 7.66 (d, J = 8.8 Hz, 2H, 2’ and 6’-
H), 7.99 (dd, J = 8.0 and 2.0 Hz, 1H, 4-H), 8.49 (br d, 1H, 6-H) 
ppm. 13C NMR (100.6 MHz, CDCl3): δ = 55.39 (OMe), 114.46 
(3’ and 5’-CH), 115.26 (3-CH), 119.76 (5-CH), 126.47 (C), 
127.86 (2’ and 6’-CH), 130.41 (4-CH), 134.60 (C), 144.59 (C), 
145.60 (6-CH), 160.24 (C), 161.04 (C) ppm. MS-EI: m/z (%) 
241 (M+, 100). HRMS: Calcd. for C14H11NOS [M+] 241.0561. 
Found 241.0561. 
In one-pot, from 3-bromo-2-chloropyridine (65.0 mg, 0.338 
mmol) and 4-ethynylanisole (1.1 equiv.) and after 
recrystallization from ether/petroleum ether, compound 31 was 
obtained as a yellow solid (60.0 mg, 74%). 
4.3 .6 .  2-(3 -Methoxyphenyl ) th ieno[2 ,3-b] pyr id ine 
(32 )  
From compound  6 (102 mg, 0.420 mmol), compound 32 
was obtained as a yellow solid (92.0 mg, 91%), m.p. 85-86 ºC. 
1H NMR (300 MHz, CDCl3): δ = 3.90 (s, 3H, OMe), 6.91-6.95 
(m, 1H), 7.24-7.39 (m, 4H), 7.46 (s, 1H, 3-H), 8.03 (dd, J = 8.0 
and 1.6 Hz, 1H, 4-H), 8.53 (dd, J = 4.8 and 1.6 Hz, 1H, 6-H) 
ppm 13C NMR (75.4 MHz, CDCl3): δ = 55.36 (OMe), 112.20 
(CH), 114.31 (CH), 116.83 (3-CH), 119.12 (CH), 119.81 (CH), 
130.08 (CH), 130.87 (4-CH), 134.26 (C), 135.06 (C), 144.51 
(C), 146.05 (6-CH), 160.00 (C), 161.15 (C) ppm. MS-EI: m/z 
(%) 241 (M+, 100). HRMS: Calcd. for C14H11NOS [M+] 
241.0561. Found 241.0563. 
In one-pot, from 3-bromo-2-chloropyridine (65.0 mg, 0.338 
mmol) and 3-ethynylanisole (1.1 equiv.) and after 
recrystallization from ether/petroleum ether, compound 32 was 
obtained as a yellow solid (50.0 mg, 62%). 
 
4.3 .7 .  2-(Thieno[2 ,3 -b] pyr id in-2-yl )pheno l  (33 )  
From compound 7 (58.0 mg, 0.240 mmol), compound 33 
was obtained as a yellow solid, (60.0 mg, 86 %), m.p. 191-192 
ºC. 1H NMR (400 MHz, acetone-d6): δ = 6.99-7.04 (m, 1H, 5-
H), 7.11-7.13 (m, 1H, 3-H), 7.26-7.30 (m, 1H, 4-H), 7.40 (dd, 
J = 8.0 and 4.8 Hz, 1H, 5’-H), 7.75-7.78 (m, 1H, 6-H), 7.94 (s, 
1H, 3’-H), 8.20 (dd, J = 8.0 and 1.6 Hz, 1H, 4’-H), 8.53 (dd, J 
= 4.8 and 1.6 Hz, 1H, 6’-H), 9.42 (br s, 1H, OH) ppm. 13C 
NMR (100.6 MHz, acetone-d6): δ = 117.46 (3-CH), 120.57 (3’-
CH), 120.60 (5’-CH), 121.05 (5-CH), 121.49 (C), 129.91 (6-
CH), 130.59 (4-CH), 131.38 (4’-CH), 134.53 (C), 141.41 (C), 
146.95 (6’-CH), 155.38 (C), 162.27 (C) ppm. MS-EI: m/z (%) 
= 227 (M+, 100). HRMS: Calcd. for C13H9NOS [M+] 227.0405. 
Found 227.0405. 
 
4.3 .8 .  2-(4 -Bromophenyl ) th ieno[2 ,3-b] pyr id ine 
(34 )  
From compound 8 (50.0 mg, 0.170  mmol), compound 34 
was obtained as a yellow  solid (35.0 mg, 71 %)  m.p.104-105 
ºC. 1H NMR (400 MHz, acetone-d6): δ = 7.46 (dd, J = 8.0 and 
4.8 Hz, 1H, 5-H), 7.72 (d, J = 8.8 Hz, 2H, 2’ and 6’-H), 7.82 
(d, J = 8.8 Hz, 2H, 3’ and 5’-H), 7.84 (s, 1H, 3-H), 8. 25 (dd, J 
= 8.0 and 1.6 Hz, 1H, 4-H), 8.57 (dd, J = 4.8 and 1.6 Hz, 1H, 
6-H) ppm. 13C NMR (100.6 MHz, acetone-d6): δ = 119.10 (3-
CH), 121.21 (6-CH), 123.25(C), 129.01 (3’ and 5’-CH), 
130.09 (C), 132.10 (4-CH), 133.15 (2’ and 6’-CH), 135.13 (C), 
143.15 (C), 147.73 (6-CH), 162.07(C) ppm. MS-EI: m/z (%) 
291 (M+ 81Br, 100), 289 (M+ 79Br, 100). HRMS: Calcd for 
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C13H879BrNS [M+] 288.9561. Found 288.9565. Calcd for 
C13H881BrNS [M+] 290.9540. Found 290.9551. 
4.3 .9 .  2-(3 -Fluorophenyl ) th ieno[2 ,3-b] pyr id ine 
(35 )  
From compound 9 (60.0 mg, 0.280 mmol), compound 35 
was obtained as a yellow solid (50.0 mg, 87%), m.p.78-79 ºC. 
1H NMR (400 MHz, acetone-d6): δ = 7.21-7.26 (m, 1H), 7.46 
(dd, J = 8.2 and 4.4 Hz, 1H, 5-H), 7.56-7.70 (m, 3H), 7.87 (s, 
1H, 3-H), 8.25 (dd, J = 8.2 and 1.6 Hz, 1H, 4-H), 8.56 (dd, J = 
4.4 and 1.6 Hz, 1H, 6-H) ppm. 13C NMR (100.6 MHz, acetone-
d6): δ = 113.73 (d, J = 24.1 Hz, CH), 116.38 (d, J = 22.1 Hz, 
CH), 119.55 (3-CH), 121.21 (5-CH), 123.32 (d, J = 3.0 Hz, 6’-
CH), 132.07 (d, J = 9.1 Hz, 5’-CH), 132.18 (4-CH), 134.97 
(C), 136.99 (d, J = 8.0 Hz, 1’-C), 142.95 (C), 147.87 (6-CH), 
162.13 (C), 164.06 (d, J = 244.5 Hz, CF) ppm. MS-EI: m/z (%) 
229 (M+, 100). HRMS: Calcd. for C13H8FNS [M+] 229.0361. 
Found 229.0365. 
4.3 .10 .  2-(Thiophen-3-yl ) th ieno[2 ,3-b] pyr id ine 
(36 )  
From compound 10 (80.0 mg, 0.370 mmol), compound 36 
was obtained as a yellow solid (66.0 mg, 82%), m.p. 109-110 
ºC.  1H NMR (400 MHz, CDCl3): δ = 7.30 (dd, J = 8.0 and 4.8 
Hz, 1H, 5-H), 7.33 (s, 1H, 3-H), 7.41-7.44 (m, 2H), 7.55-7.59 
(m, 1H), 8.01 (dd, J = 8.0 and 1.6 Hz, 1H, 4-H), 8.50 (br d, 1H, 
6-H) ppm. 13C NMR (100.6 MHz, CDCl3): δ = 116.38 (3-CH), 
119.85 (5-CH), 122.32 (CH), 125.77 (CH), 126.92 (CH), 
130.85 (4-CH), 134.33 (C), 135.16 (C), 139.51 (C), 145.59 (6-
CH), 160.48 (C) ppm. MS-EI: m/z (%) 217 (M+, 100). HRMS: 
Calcd. for C11H7NS2 [M+] 217.0020. Found 227.0023. 
 
In one-pot, from 3-bromo-2-chloropyridine (65.0 mg, 0.338 
mmol) and 3-ethynylthiophene (1.1 equiv.) and after 
purification by dry flash chromatography using a solvent 
gradient from neat petroleum ether to 20% ether/petroleum 
ether, compound 36 was obtained as a yellow solid (44.0 mg, 
60%). 
4.3 .11 .  2-(Pyrid in -3-yl ) th ieno[2 ,3-b] pyr id ine (37 )  
From compound 11 (101 mg, 0.471 mmol), compound 37 
was obtained as a brown solid (70.0 mg, 70%). 
Recrystallization from ether/petroleum ether gave brown 
crystals, m.p. 86-88 ºC. 1H NMR (400 MHz, CDCl3): δ = 7.31 
(dd, J = 8.0 and 4.8 Hz, 1H, 5-H), 7.40-7.44 (m, 1H, 5’-H), 
7.54 (s, 1H, 3-H), 8.00-8.03 (m, 1H), 8.06 (dd, J = 8.0 and 1.6 
Hz, 1H, 4-H), 8.56 (dd, J = 4.8 and 1.6 Hz, 1H, 6-H), 8.61 (br 
dd, 1H, 6’-H), 9.01 (br d, 1H, 2’-H) ppm. 13C NMR (100.6 
MHz, CDCl3): δ = 118.27 (3-CH), 120.09 (5-CH), 123.98 (6’-
CH), 130.24 (C), 131.13 (4-CH), 133.81 (C), 134.29 (4’-CH), 
140.21 (C), 146.72 (2’-CH), 146.96 (6-CH), 148.86 (6’-CH), 
161.61 (C) ppm. MS-EI: m/z (%) 212 (M+, 100). HRMS: 
Calcd. for C12H8N2S [M+] 212.0408. Found 212.0407. 
In one-pot, from 3-bromo-2-chloropyridine (80.0 mg, 0.416 
mmol) and 3-ethynylpyridine (1.1 equiv.) and after purification 
by dry flash chromatography using neat ether as the solvent, 
compound 37 was obtained as an off-white solid (62.0 mg, 
70%). 
4.3 .12 .  2-(Pyrid in -2-yl ) th ieno[2 ,3-b] pyr id ine (38 )  
From compound 12 (60.0 mg, 0.280 mmol), compound 38 
was obtained as a colourless oil (50.0 mg, 86%). 1H NMR (400 
MHz, acetone-d6): δ = 7.39-7.41 (m, 1H), 7.44 (dd, J = 8.0 and 
4.8 Hz, 1H, 5-H), 7.92-7.97 (m, 1H), 8.08 (s, 1H, 3-H), 
8.10-8.13 (m, 1H), 8.26 (dd, J = 8.0 and 1.6 Hz, 1H, 4-H), 8.58 
(dd, J = 4.8 and 1.6 Hz, 1H, 6-H), 8.65-8.67 (m, 1H) ppm.  13C 
NMR (100.6 MHz, acetone-d6): δ = 119.81 (3-CH), 120.34 
(CH), 120.90 (5-CH), 121.09 (C), 124.25 (CH), 132.36 (4-
CH), 134.92 (C), 137.86 (CH), 146.00 (C), 148.06 (6-CH), 
150.56 (CH), 163.05(C) ppm. MS-EI: m/z (%) 212 (M+, 100). 
HRMS: Calcd. for C12H8N2S [M+] 212.0408. Found 212.0406. 
In one-pot, from 3-bromo-2-chloropyridine (65.0 mg, 0.338 
mmol) and 2-ethynylpyridine (1.1 equiv.) and after purification 
by dry flash chromatography using neat ether as the solvent, 
compound 38 was obtained as an off-white solid (47.0 mg, 
66%). 
4.3 .13 .  2-(1 -Methy l-1H-imidazol -5-yl ) th ieno[2 ,3 -
b] pyr id ine (39 )  
From compound 13 (100 mg, 0.466 mmol), compound 39 
was obtained as an off-white solid (70.0 mg, 71%). 
Recrystallization from ether/petroleum ether gave off-white 
crystals, m.p. 78-80 ºC. 1H NMR (400 MHz, CDCl3): δ = 3.85 
(s, 3H, NMe), 7.24 (s, 1H, 3-H), 7.32 (dd, J = 8.0 and 4.8 Hz, 
1H, 5-H), 7.35 (br s, 1H), 7.66 (br  s, 1H), 8.03 (dd, J = 8.0 and 
1.6 Hz, 1H, 4-H), 8.54 (dd, J = 4.8 and 1.6 Hz, 1H, 6-H) ppm. 
13C NMR (100.6 MHz, CDCl3): δ = 33.19 (NMe), 119.14 (3-
CH), 119.96 (5-CH), 126.74 (C), 130.18 (CH), 130.74 (4-CH), 
131.29 (C), 133.27 (C), 140.21 (CH), 146.71 (6-CH), 161.45 
(C) ppm. MS-EI: m/z (%) 215 (M+, 100). HRMS: Calcd. for 
C11H9N3S [M+] 215.0517. Found 215.0518. 
In one-pot, from 3-bromo-2-chloropyridine (65.0 mg, 0.338 
mmol) and 5-ethynyl-1-methyl-1H-imidazole (1.1 equiv.) and 
after recrystallization from ether/petroleum ether, compound 
39 was obtained as an off-white solid (47.0 mg, 66%). 
4.3 .14 .  2-Phenyl th ieno[3 ,2-b] pyr id ine (40 )  
From compound 14 (80.0 mg, 0.374 mmol), compound 40 
was obtained as an orange solid (63.0 mg, 80%). 
Recrystallization from ether/petroleum ether gave orange 
crystals, m.p. 115-117 ºC. 1H NMR (400 MHz, CDCl3): δ = 
7.22 (dd, J = 8.2 and 4.4 Hz, 1H, 6-H), 7.38-7.49 (m, 3H), 
7.75-7.77 (m, 3H), 8.13 (m, 1H, 7-H), 8.67 (dd, J = 4.4 and 1.6 
Hz, 1H, 5-H) ppm. 13C NMR (100.6 MHz, CDCl3): δ = 118.60 
(6-CH), 120.50 (3-CH), 126.48 (2×CH), 129.07 (2×CH), 
129.10 (CH), 130.01 (7-CH), 133.38 (C), 133.63 (C), 147.46 
(5-CH), 148.32 (C), 156.86 (C) ppm. MS-EI: m/z (%) 211 (M+, 
100). HRMS: Calcd for C13H9NS [M+] 211.0456. Found 
211.0459. 
In one-pot, from 2-bromo-3-chloropyridine (70.0 mg, 0.364 
mmol) and phenylacetylene (1.1 equiv.) and after 
recrystallization from ether/petroleum ether, compound 40 was 
obtained as an orange solid (72.0 mg, 94%). 
4.3 .15 .   4 -(Thieno[3 ,2-b] pyr id in-2-yl )ani l ine (41 )  
From compound 15 (134.0 mg, 0.586 mmol), compound 41 
was obtained as a brown solid (113 mg, 85%). 
Recrystallization from ether/petroleum ether gave brown 
crystals, m.p. 142-144 ºC. 1H NMR (400 MHz, DMSO-d6): δ = 
5.59 (br s, 2H, NH2), 6.64 (d, J = 8.4 Hz, 2H, 2 and 6-H), 7.22 
(dd, J = 8.2 and 4.8 Hz, 1H, 6’-H), 7.52 (d, J = 8.4 Hz, 2H, 3 
and 5-H), 7.63 (s, 1H, 3’-H), 8.29-8.33 (m, 1H, 7’-H), 8.53 
(dd, J = 4.8 and 1.6 Hz, 1H, 5’-H) ppm. 13C NMR (100.6 MHz, 
DMSO-d6): δ = 113.89 (2 and 6-CH), 116.29 (3’-CH), 118.04 
(6’-CH), 118.51 (C), 120.19 (C), 127.24 (3 and 5-CH), 130.10 
(7’-CH), 147.10 (5’-CH), 149.13 (C), 150.28 (C), 157.18 (C) 
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ppm. MS-EI: m/z (%) 226 (M+, 100). HRMS: Calcd. for 
C13H10N2S [M+] 226.0565. Found 226.0568.  
In one-pot, from 2-bromo-3-chloropyridine (96.0 mg, 0.500 
mmol) and 4-ethynylaniline (1.1 equiv.) and after purification 
by dry flash chromatography using neat ether, compound 41 
was obtained as a brown solid (74.0 mg, 65%). 
 
4.3 .16 .  3-(Thieno[3 ,2 -b] pyr id in-2-yl )ani l ine (42 )  
From compound 16 (67.0 mg, 0.293 mmol), compound 42 
was obtained as a yellow solid (57.0 mg, 86%), m.p. 145-146 
ºC. 1H NMR (400 MHz, DMSO-d6): δ = 5.31 (br s, 2H, NH2), 
6.62-6.64 (m, 1H, 6-H), 6.99-7.01 (m, 2H, 2 and 4-H), 7.11-
7.15 (m, 1H, 5-H), 7.31 (dd, J = 8.0 and 4.4 Hz, 1H, 6’-H), 
7.78 (s, 1H, 3’-H), 8.41 (dd, J = 8.0 and 1.2 Hz, 1H, 7’-H), 
8.61 (dd, J = 4.4 and 1.2 Hz, 1H, 5’-H) ppm. 13C NMR (100.6 
MHz, DMSO-d6): δ = 111.10 (CH), 113.70 (CH), 114.95 (6-
CH), 118.87 (6’-CH), 119.56 (3’-CH), 129.77 (5-CH), 130.55 
(7’-CH), 132.30 (C), 133.44 (C), 147.45 (5’-CH), 148.60 (C), 
149.36 (C), 156.44 (C) ppm. MS-EI: m/z (%) 226 (M+, 100). 
HRMS: Calcd. for C13H10N2S [M+] 226.0565. Found 226.0564.  
4.3 .17 .  2-(Thieno[3 ,2 -b] pyr id in-2-yl )ani l ine (43 )  
From compound 17 (50.0 mg, 0.220  mmol), compound 43 
was obtained as an brown oil (47 mg, 94 %). 1H NMR (400 
MHz, DMSO-d6): δ = 5.35 (br s, 2H, NH2), 6.65-6.69 (m, 1H, 
4-H), 6.83-6-86 (m, 1H, 6-H), 7.10-7.15 (m, 1H, 5-H), 7.27-
7.30 (m, 1H, 3-H), 7.33 (dd, J = 8.2 and 4.8 Hz, 1H, 6’-H), 
7.65 (s, 1H, 3’-H), 8.42 (dd, J = 8.2 and 1.6 Hz, 1H, 7’-H), 
8.63 (dd, J = 4.8 and 1.6 Hz, 1H, 5’-H) ppm. 13C NMR (100.6 
MHz, DMSO-d6): δ = 116.20 (6-CH), 116.78 (4-CH), 117.41 
(C), 118.70 (6’-CH), 122.14 (3’-CH), 129.84 (5-CH), 130.09 
(3-CH), 130.24 (7’-CH), 132.41 (C), 146.00 (C), 146.09 (C), 
147.21 (5’-CH), 156.42 (C) ppm. MS-EI: m/z (%) 226 (M+, 
100). HRMS: Calcd. for C13H10N2S [M+] 226.0565. Found 
226.0563. 
In one-pot, from 2-bromo-3-chloropyridine (65.0 mg, 0.338 
mmol) and 2-ethynylaniline (1.1 equiv.) and after purification 
by dry flash chromatography using neat ether as the solvent, 
compound 43 was obtained as a beige solid (62.0 mg, 80%). 
 
4.3 .18 .  2-(4 -Methoxyphenyl ) th ieno[3 ,2-b] pyr id ine 
(44 )  
From compound 18 (94.0 mg, 0.380 mmol) compound 44 
was obtained as a yellow solid (90.0 mg, 97%). 
Recrystallization from ether/petroleum ether gave yellow 
crystals, m.p. 106-107  ºC. 1H NMR (400 MHz, acetone-d6): δ 
= 3.91 (s, 3H, OMe), 7.10 (d, J = 8.8 Hz, 2H, 3’ and 5’-H), 
7.31 (dd, J = 8.2 and 4.8 Hz, 1H, 6-H), 7.77 (s, 1H, 3-H), 7.83 
(d, J = 8.8 Hz, 2H, 2’ and 6’-H), 8.34 (dd, J = 8.2 and 1.2 Hz, 
1H, 7-H), 8.65 (dd, J = 4.8 and 1.2 Hz, 1H, 5-H) ppm. 13C 
NMR (100.6 MHz, acetone-d6): δ = 55.76 (OMe), 115.44 (3’ 
and 5’-CH), 119.44 (6-CH), 120.05 (3-CH), 123.99 (C), 
127.01 (C), 128.51 (2’ and 6’-CH), 130.73 (7-CH), 148.32 (5-
CH), 148.78 (C), 158.24 (C), 161.63 (C) ppm. MS-EI: m/z (%) 
241 (M+, 100). HRMS: Calcd. for C14H11NOS [M+] 241.0561. 
Found 241.0563. 
In one-pot, from 2-bromo-3-chloropyridine (65.0 mg, 0.338 
mmol) and 4-ethynylanisole (1.1 equiv.) and after 
recrystallization from ether/petroleum ether, compound 44 was 
obtained as a beige solid (70.0 mg, 86%). 
4.3 .19 .  2-(3 -Methoxyphenyl ) th ieno[3 ,2-b] pyr id ine 
(45 )  
From compound 19 (119 mg, 0.480 mmol) compound 45 
was obtained as a yellow solid (110 mg, 95%). 
Recrystallization from ether/petroleum ether gave yellow 
crystals, m.p. 85-86 ºC. 1H NMR (400 MHz, CDCl3): δ = 3.89 
(s, 3H, OMe), 6.94-6.97 (m, 1H), 7.25 (dd, J = 8.0 and 4.8 Hz, 
1H, 6-H), 7.27-7.28 (m, 1H), 7.35-7.38 (m, 2H), 7.80 (s, 1H, 3-
H), 8.15-8.17 (m, 1H, 7-H), 8.65-8.67 (m, 1H, 5-H) ppm. 13C 
NMR (100.6 MHz, CDCl3): δ = 55.57 (OMe), 112.18 (CH), 
114.70 (CH), 118.64 (6-CH), 119.07 (CH), 120.23 (3-CH), 
130.15 (CH), 130.55 (7-CH), 133.64 (C), 134.76 (C), 146.81 
(5-CH), 148.82 (C), 156.08 (C), 160.03 (C) ppm. MS-EI: m/z 
(%) 241 (M+, 100). HRMS: Calcd. for C14H11NOS [M+] 
241.0561. Found 241.0560. 
In one-pot, from 2-bromo-3-chloropyridine (96.0 mg, 0.500 
mmol) and 3-ethynylanisole (1.1 equiv.) and after 
recrystallization from ether/petroleum ether, compound 45 was 
obtained as a beige solid (101 mg, 84%). 
 
4.3 .20 .  2-(Thieno[3 ,2 -b] pyr id in-2-yl )pheno l  (46 )  
From compound 20 (121 mg, 0.490 mmol) compound 46 
was obtained as a white solid which was washed with CHCl3 
(70.0 mg, 64%), m.p. 136-137 ºC. 1H NMR (400 MHz, 
acetone-d6): δ = 7.01-7.05 (m, 1H, 4-H), 7.13-7.16 (m, 1H, 6-
H), 7.28-7.35 (m, 2H, 6’ and 5-H), 7.81-7.83 (m, 1H, 3-H), 
8.12 (m, 1H, 3’-H), 8.35-8.38 (m, 1H, 7’-H), 8.68 (br s, 1H, 5’-
H), 9.63 (br s, 1H, OH) ppm. 13C NMR (100.6 MHz, acetone-
d6): δ = 117.53 (6-CH), 119.37 (6’-CH), 121.04 (4-CH), 
121.24 (C), 123.51 (3’-CH), 129.67 (3-CH), 130.58 (7’-CH), 
130.92 (5-CH), 133.97 (C), 145.57 (C), 147.96 (5’-CH), 
155.49 (C), 157.48 (C) ppm. MS-EI: m/z (%) 227 (M+, 100). 
HRMS: Calcd. for C13H9NOS [M+] 227.0405. Found 227.0405. 
 
4.3 .21 .  2-(4 -Bromophenyl ) th ieno[3 ,2-b] pyr id ine 
(47 )  
From compound 21 (50.0 mg, 0.170 mmol), compound 47 
was obtained as a yellow solid (45.0 mg, 94 %), m.p. 104-105 
ºC. 1H NMR (400 MHz, acetone-d6): δ = 7.35 (dd, J = 8.0 and 
4.4 Hz, 1H, 6-H), 7.54 (d, J = 8.8 Hz, 2H, 2’ and 6’-H), 7.90 
(d, J = 8.8 Hz, 2H, 3’ and 5’-H), 7.99 (s, 1H, 3-H), 8.39 (dd, J 
= 8.0 and 1.2 Hz, 1H, 7-H), 8.69 (br d, 1H, 5-H) ppm. 13C 
NMR (100.6 MHz, acetone-d6): δ = 119.83 (6-CH), 121.53 (3-
CH), 127.12 (3’ and 5’-CH), 130.05 (C), 130.08 (2’ and 6’-
CH), 130.94 (7-CH), 133.94 (C), 134.47 (C), 148.51 (5-CH), 
148.69 (C), 157.94 (C) ppm. MS-EI: m/z (%) 291 (M+ 81Br, 
100), 289 (M+ 79Br, 100). HRMS: Calcd for C13H879BrNS [M+] 
288.9561. Found 288.9565. Calcd for C13H881BrNS [M+] 
290.9540. Found 290.9549. 
 
4.3 .22 .  2-(3 -Fluorophenyl ) th ieno[3 ,2-b] pyr id ine 
(48 )   
From compound 22 (30.0 mg, 0.130 mmol), compound 48 
was obtained as a yellow solid (25.0 mg, 85%), m.p. 122-123 
ºC. 1H NMR (400 MHz, acetone-d6): δ = 7.25-7.28 (m, 1H), 
7.32 (dd, J = 8.2 and 4.8 Hz, 1H, 6-H), 7.56-7.62 (m, 1H), 
7.68-7.74 (m, 2H), 8.00 (s, 1H, 3-H), 8.42 (dd, J = 8.2 and 1.6 
Hz, 1H, 7-H), 8.71 (dd, J = 4.8 and 1.6 Hz, 1H, 5-H) ppm. 13C 
NMR (100.6 MHz, acetone-d6): δ = 113.79 (d, J = 23.1 Hz, 
CH), 116.64 (d, J = 21.1 Hz, CH), 120.18 (6-CH), 122.73 (3-
 13 
CH), 123.18 (d, J = 3.0 Hz, 6’-CH), 131.08 (7-CH), 132.08 (d, 
J = 8.0 Hz, 5’-CH), 134.12 (C), 137.83 (d, J = 8.0 Hz, 1’-C) 
143.32 (C), 148.75 (5-CH), 157.71 (C), 164.06 (d, J = 224.5 
Hz, C-F). MS-EI: m/z (%) 229 (M+, 100). HRMS: Calcd. for 
C13H8FNS [M+] 229.0361. Found 229.0362. 
4.3 .23 .  2-(Thiophen-3-yl ) th ieno[3 ,2-b] pyr id ine 
(49 )  
From compound 23 (50.0 mg, 0. 230 mmol), compound 49 
was obtained as a yellow solid (40.0 mg, 80%), m.p. 98-99 ºC. 
1H NMR (400 MHz, CDCl3): δ = 7.25-7.29 (m, 1H), 7.42-7.46 
(m, 2H), 7.63-7.64 (m, 1H), 7.69 (s, 1H, 3-H), 8.15 (br d, 1H, 
7-H), 8.66 (br s, 1H, 5-H) ppm. 13C NMR (100.6 MHz, 
CDCl3): δ = 118.55 (CH), 119.46 (3-CH), 122.74 (CH), 125.97 
(CH), 127.09 (CH), 130.82 (7-CH), 133.48 (C), 134.91 (C), 
143.96 (C), 146.26 (5-CH), 155.64 (C) ppm. MS-EI: m/z (%) 
217 (M+, 100). HRMS: Calcd. for C11H7NS2 [M+] 217.0020. 
Found 217.0021. 
 
In one-pot, from 2-bromo-3-chloropyridine (65.0 mg, 0.338 
mmol) and 3-ethynylthiophene (1.1 equiv. ) and after 
purification by dry flash chromatography using a solvent 
gradient from neat petroleum ether to 20% ether/petroleum 
ether, compound 49 was obtained as a beige solid (54.0 mg, 
73%). 
 
4.3 .24 .  2-(Pyrid in -3-yl ) th ieno[3 ,2-b] pyr id ine (50 )  
From compound 24 (60.0 mg, 0.279 mmol), compound 50 
was obtained as an orange solid (41.0 mg, 70%). 
Recrystallization from ether/petroleum ether gave orange 
crystals, m.p. 153-154 ºC. 1H NMR (400 MHz, CDCl3): δ = 
7.26 (dd, J = 8.2 and 4.6 Hz, 1H, 6-H), 7.39 (dd, J = 8.0 and 
4.8 Hz, 1H, 5’-H), 7.83 (s, 1H, 3-H), 8.01-8.02 (m, 1H, 4’-H), 
8.16-8.19 (dd, J = 8.2 and 1.2Hz,  1H, 7-H), 8.62 (br d, 1H, 6’-
H), 8.68 (dd, J = 4.6 and 1.2 Hz, 1H, 5-H), 9.00 (br s, 1H, 2’-
H) ppm. 13C NMR (100.6 MHz, CDCl3): δ = 119.08 (6-CH), 
121.51 (3-CH), 123.80 (5’-CH), 129.63 (C), 130.50 (7-CH), 
133.63 (4’-CH), 133.73 (C), 144.61 (C), 147.29 (CH), 147.35 
(CH), 149.91 (6’-CH), 156.00 (C) ppm.  MS-EI: m/z (%) 212 
(M+, 100). HRMS: Calcd. for C12H8N2S [M+] 212.0408. Found 
212.0414. 
In one-pot, from 2-bromo-3-chloropyridine (65.0 mg, 0.338 
mmol) and 3-ethynylpyridine (1.1 equiv.) and after 
recrystallization from ether/petroleum ether, compound 50 was 
obtained as a beige solid (55.0 mg, 77%). 
4.3 .25 .   2 -(Pyrid in -2 -yl ) th ieno[3 ,2-b] pyr id ine 
(51 )  
From compound 25 (100 mg, 0.466 mmol), compound 51 
was obtained as an orange solid (70.0 mg, 71%). 
Recrystallization from ether/petroleum ether gave orange 
crystals, m.p. 153-155 ºC. 1H NMR (400 MHz, CDCl3): δ = 
7.28-7.31 (m, 2H), 7.77-7.81 (m, 1H), 7.89-7.91 (m, 1H), 8.06 
(s, 1H, 3-H), 8.24 (br d, 1H), 8.65-8.68 (m, 2H) ppm. 13C NMR 
(100.6 MHz, CDCl3): δ = 119.19 (CH), 119.96 (CH), 120.98 
(3-CH), 123.59 (CH), 131.21 (CH), 135.13 (C), 136.87 (CH), 
146.62 (CH), 149.75 (CH), 149.89 (C), 151.49 (C), 155.64 (C) 
ppm. Anal. Calcd for C12H8N2S (212.27): C, 67.90; H, 3.80; N, 
13.20; S, 15.11. Found: C, 67.66; H, 4.01; N, 12.93; S, 14.89. 
In one-pot, from 2-bromo-3-chloropyridine (65.0 mg, 0.338 
mmol) and 2-ethynylpyridine (1.1 equiv.) and after 
recrystallization from ether/petroleum ether, compound 51 
was obtained as a beige solid (56.0 mg, 78%). 
4.3 .26 .  2-(1 -Methy l-1H-imidazol -5-yl ) th ieno[3 ,2 -
b] pyr id ine (52 )  
From compound 26 (75.0 mg, 0.450 mmol), compound 52 
was obtained as an off-white solid (40.0 mg, 54%). 
Recrystallization from ether/petroleum ether gave off-white 
crystals, m.p. 110-112 ºC. 1H NMR (400 MHz, CDCl3): δ = 
3.86 (s, 3H, NMe), 7.24 (dd, J = 8.2 and 4.6 Hz, 1H, 6-H), 7.39 
(br s, 1H), 7.52 (s, 1H, 3-H), 7.65 (br s, 1H), 8.23 (dd, J = 8.2 
and 1.4 Hz, 1H, 7-H), 8.54 (dd, J = 4.6 and 1.4 Hz, 1H, 5-H) 
ppm. 13C NMR (100.6 MHz, CDCl3): δ = 33.25 (NMe), 118.92 
(6-CH), 121.76 (3-CH), 126.51 (C), 129.83 (7-CH), 130.41 
(CH), 132.99 (C), 135.29 (C), 140.61 (CH), 147.60 (5-CH), 
156.23 (C) ppm. MS-EI: m/z (%) 215 (M+, 100). HRMS: 
Calcd. for C11H9N3S [M+] 215.0517. Found 215.0519. 
In one-pot, from 2-bromo-3-chloropyridine (96.0 mg, 0.500 
mmol) and 5-ethynyl-1-methyl-1H-imidazole (1.1 equiv.) and 
after recrystallization from ether/petroleum ether, compound 
52 was obtained as an off-white solid (74.0 mg, 69%). 
 
4.4. Synthesis of 1-(4-methoxyphenyl)-3-[2-(thieno[3,2-
b]pyridin-2-yl)phenyl]urea (53):  
Thienopyridine 43 (30.0 mg, 0.120 mmol) and 4-
methoxyphenylisocyanate (1 equiv.) were left stirring in 6 mL 
THF:CH2Cl2 (1:1) at room temperature for 16 h. A precipitate 
did not come out after this time and hexane (3-5 mL) was 
added to the mixture and the precipitate formed was filtered 
under vacuum. Compound 53 was obtained as a yellow solid 
(20.0 mg, 90%), m.p. 199-200 ºC. 1H NMR (400 MHz, 
DMSO-d6): δ  = 3.69 (s, 3H, OMe), 6.83 (d, J = 8.8 Hz, 2H, 3’ 
and 5’-H), 7.16-7.21 (m, 1H), 7.31 (d, J = 8.8 Hz, 2H, 2’ and 
6’-H), 7.36-7.44 (m, 2H), 7.53-7.55 (m, 1H), 7.71 (s, 1H, 3’’’-
H), 7.92-7.95 (m, 1H), 8.02 (br s, 1H, NH), 8.47-8.50 (m, 1H), 
8.67-8.68 (m, 1H, 5’’’-H) 8.84 (br s, 1H, NH) ppm. 13C NMR 
(100.6 MHz, DMSO-d6): δ = 55.12 (OMe), 113.97 (3’ and 5’-
CH), 119.11 (CH), 119.84 (2’ and 6’-CH), 123.22 (CH), 
123.43 (CH), 124.18 (3’’’-CH), 125.01 (C), 129.49 (CH), 
130.36 (CH), 130.58 (CH), 132.63 (C), 133.56 (C), 136.63 (C), 
144.26 (C), 147.42 (5’’’-CH), 152.76 (C), 154.44 (C), 155.91 
(C) ppm. MS-ESI: m/z (%) 376 (M+ +H, 100). HRMS: Calcd 
for C21H18N3O2S [M+ ] 376.1114. Found 376.1111. 
 
4.5. General conditions for the bromination in position 3: 
In a dry Schlenk tube, thienopyridines 27, 37 or 40 were put in 
dry Et2O or dry CH2Cl2. Then, Br2 (1.1 equiv.) was added 
dropwise at 0 ºC and the solution was stirred at this 
temperature for 30 min to 1h. Then the mixture was diluted 
with H2O and extracted with ethyl acetate. The combined 
organic layers were dried over anhydrous MgSO4, filtered, and 
the solvent was removed under reduced pressure. The resulting 
crudes were submitted to column chromatography or PLC to 
give the expected 3-bromo-2-phenylpyridines. 
4.5 .1 .  3-Bromo-2-phenyl th ieno[2 ,3-b] pyr id ine 
(54)  
From compound 27 (60.0 mg, 0.284 mmol), and after 
purification by PLC using neat Et2O as eluent, compound 54 
was obtained as a yellow solid (33.0 mg, 40%), m.p. 54-55 ºC. 
1H NMR (400 MHz, CDCl3): δ  = 7.44−7.54 (m, 4H), 7.77-
7.80 (m, 2H), 8.14 (dd, J = 8.0 and 1.6 Hz, 1H, 4-H), 8.62 (br 
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d, 1H, 6-H). 13C NMR (100.6 MHz, CDCl3): δ = 102.30 
(C), 120.51 (CH), 128.73 (2×CH), 129.28 (CH), 129.64 
(2×CH), 131.43 (4-CH), 132.38 (C), 133.64 (C), 139.23 (C), 
147.06 (6-CH), 158.74 (C). MS-EI: m/z (%) 291 (M+ 81Br, 99), 
289 (M+ 79Br, 100). HRMS: Calcd for C13H879BrNS [M+] 
288.9561. Found 288.9555. Calcd for C13H881BrNS [M+] 
290.9540. Found 290.9533. 
 
4.5 .2 .  3-Bromo-2-phenyl th ieno[3 ,2-b] pyr id ine 
(55 )  
From compound 40 (69.0 mg, 0.328 mmol), and after 
purification by column chromatography using 40% 
ether/petroleum ether,  compound 55 was obtained as an off-
white solid (40.0 mg, 42%), m.p 109-111 oC (lit3d 110-112 oC). 
1H NMR (400 MHz, CDCl3): δ  =7.36-7.39 (br m, 1H, 6-H), 
7.49-7.55 (m, 3H), 7.81-7.83 (m, 2H), 8.20 (br d, 1H, 7-H), 
8.85 (br s, 1H, 5-H). 13C NMR (100.6 MHz, CDCl3): δ = 
107.05 (C), 119.90 (6-CH), 128.79 (2×CH), 129.47 (2×CH), 
129.51 (4’CH), 130.75 (7-CH), 132.57 (C), 133.18 (C), 142.77 
(C), 147.90 (5-CH), 152.79 (C), 161.46 (C) ppm. MS-EI: m/z 
(%) = 211 (M+, 100). 
 
4.5 .3 .  3-Bromo-2-pyr id in -3-yl - th ieno[2 ,3-
b] pyr id ine (56 )  
From compound 37 (30.0 mg, 0.142 mmol), and after 
purification by recrystallization with ether/petroleum ether, 
compound 56 was obtained as an ocre solid (27.0 mg, 65%), 
m.p. 201-203 ºC. 1H NMR (400 MHz, CDCl3): δ = 7.49 (dd, J 
= 8.0 and 4.8 Hz, 1H, 5-H), 7.64-7.69 (br m, 1H, 5’-H), 8.15 
(dd, J = 8.0 and 1.6 Hz, 1H, 4-H), 8.30 (br d, 1H, 4’-H), 8.68 
(dd, J = 4.8 and 1.6 Hz, 1H, 6-H), 8.79 (br s, 1H, 6’-H), 9.13 
(br s, 1H, 2’-H). 13C NMR (100.6 MHz, CDCl3): δ = 120.95 
(5-CH), 124.61 (5’-CH), 131.71 (4-CH), 131.93 (C), 132.96 
(C), 139.40 (4’-CH), 142.74 (C), 147.03 (6’-CH), 147.25 (2’-
CH), 148.53 (6-CH), 159.29 (C), 161.59 (C). MS-EI: m/z (%) 
292 (M+81Br, 100), 290 (M+79Br, 93). HRMS: Calcd. for 
C12H779BrN2S [M+] 289.9513. Found 289.9507. Calcd. for 
C12H781BrN2S [M+] 291.9493. Found 291.9492. 
 
4.6. Chlorination of the thieno[2,3-b]pyridine 32: 
4.6 .1 .  4-Chloro -2- (3 -methoxyphenyl ) th ieno[2 ,3 -
b] pyr id ine (57 )  
To compound 32 (60.0 mg, 0.250 mmol) in 6 mL 
DME/hexane (1:2), MCPBA (1.2 equiv.) was added 
portionwise at 0 oC and the mixture was left stirring for 40h at 
rt, following the reaction by tlc. After this time the solvents 
were evaporated and the resulting solid was put in CHCl3 and 
POCl3 (19.5 equiv) was added dropwise at 0 oC. After 3h the 
reaction was completed, ice H2O and Na2CO3 sat. were added 
and the reaction was extracted with CHCl3. The organic phases 
were collected, dried with MgSO4, filtered and evaporated to 
give a brown oil. This was submitted to PLC ether/petroleum 
ether 2:1 and compound 57 was obtained as a yellow solid 
(60.0 mg, 86%) m.p 95-96 oC. 1H NMR (400 MHz, CDCl3): δ 
=  3.90 (s, 3H, OMe), 7.35-7.45 (m, 3H), 7.58-7.61 (m, 1H), 
7.62 (s, 1H, 3-H), 8.00-8.03 (m, 1H), 8.10-8.11 (m, 1H), 8.50 
(br s, 1H, 6-H) ppm. 13C NMR (100.6 MHz, CDCl3): δ = 55.45 
(OMe), 114.96 (3-CH), 119.28 (CH), 120.26 (C), 128.27 (CH), 
129.80 (CH), 130.23 (CH), 131.11 (C), 133.77 (CH), 134.67 
(C), 138.65 (C), 160.00 (C), 145.86 (6-CH), 160.11 (3’-C) 
ppm. MS-EI: m/z (%) 277 (M+ 37Cl, 29), 275 (M+ 35Cl, 100). 
HRMS: Calcd for C14H1035ClNSO [M+] 275.0172. Found 
275.0165. Calcd for C14H1037ClNSO [M+] 277.0142. Found 
277.0139. 
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